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the etiology and course of depressive symptoms in patients 
with schizophrenia
Schizophrenia  is a psychiatric disease with severe consequences for mental health 
and  social  functioning.  For  most  patients  schizophrenia  is  a  chronic  disease,  yet 
some  of  them may  recover  substantially  from  their  (social)  disabilities.1,2  Patients 
with schizophrenia tend to hear voices and have delusional ideas (positive symptoms), 
suffer  from  inability  to  experience  pleasure  (anhedonia)  and  social  withdrawal 
(negative symptoms).3 Depressive symptoms are also common among patients with 
schizophrenia. About 40% of the patients have sub-syndromal depressive symptoms, 






with  poor  outcome  on  recovery  and  reintegration  into  the  community.12  The  risk 
of  suicide  or  suicidal  attempts  is  also  elevated  in  patients with  schizophrenia  and 
depressive symptoms.13-16
Patients may experience depressive symptoms throughout all phases of  illness,17,18 
and  the  prevalence  of  depressive  symptoms  is  independent  from  the  duration  of 
illness.19 Depressive  symptoms  can  be  intrinsic  to  schizophrenia  and  occur  during 
acute psychosis,20 or they can be a prodromal sign for an upcoming psychotic episode.21 
In patients with remitted psychotic symptoms, depressive symptoms may represent 



















Recognition  of  depressive  symptoms  is  complicated  in  patients with  schizophrenia 
because the DSM-IV diagnostic criteria for a major depressive episode (MDE) overlap 
with negative symptoms.6,23-25 For example, flattened affect is also a negative symptom. 





effects,  without  the  observable  (motor)  extrapyramidal  symptoms  (EPS).25  Other 
organic  factors  which  can  induce  depressive  symptoms  are  substance  abuse  or 
sudden withdrawal of illicit drugs or alcohol.20,27 Another complicating factor is that 


























































towards  other  people. He  is  not  very  confident  in  the  future,  but would  like  to 
give  life  another  try.  His  depressive  symptoms  continue  to  be  prominent  and 
distressing, although he has the idea that they pass into emotional flattening. 
The  clinician  investigated  whether  the  emotional  symptoms  reflect  negative 









Mr.  B.  with  depression.  The  symptoms  were  indicative  for  a  developmental 
disorder,  which  needed  additional  investigation  of  his  personal  history.  The 
clinician considered switching to clozapine in the presence of persistent positive 







monitoring depressive symptoms  Widely  used  guidelines  recommend  a 
careful differential diagnosis of depression in patients with schizophrenia, considering 
factors such as medication side effects.28-30 These guidelines, however, do not advise 




Many  depression  instruments  are  available  to measure  depressive  symptoms,  but 
they  vary  in  reliability  and  validity  in  patients with  schizophrenia. Most  depression 
instruments  primarily  developed  for  use  among depressed patients  do  not  appear 
to  selectively  discriminate  depressive  symptoms  from  other  symptom  dimensions 







clinical  practice  to  save  time  and  costs.35  Furthermore,  systematic  use  of  patient-
reported outcomes for the monitoring of depressive symptoms has shown to facilitate 
decision making in routine clinical care of patients with depression.38
wo  self-report  instruments  that  can  be  used  for  the  measurement  of  depressive 
symptoms  in  schizophrenia  received  relatively  little  attention  in  the  international 
literature.  The  Quick  Inventory  of  Depressive  Symptoms  (QIDS-SR16)  has  good 
psychometric  properties  in  patients  with  depressive  disorders  and  is  sensitive  to 
symptomatic changes.39,40 The presence of psychotic symptoms did not meaningfully 
affect the propensity of self-rating to recognize depressive symptoms in patients with 
major  depressive  disorder.41  The  CES-D  is  an  easy-to-use  depression  instrument, 
developed to monitor sub-syndromal depressive symptoms in the general population. 
The CES-D discriminates depressive symptoms from negative symptoms,42 and the 
predictive  validity of  the CES-D has been shown  to be sufficient  to detect  cases of 













performance  of  the  latter  instruments  has  not  extensively  been  investigated  in  a 
population of patients with schizophrenia. 
monitoring depressive symptoms in response to antipsychotics
Patients  frequently attribute depressive symptoms  to  the use of  antipsychotics.44-46 




between  patient  reports  of  subjective  experiences  and  their  levels  of  dopamine 
D2 receptor  occupancy  by  antipsychotic  drugs.
50  Furthermore,  an  interview  may 




using  the  Liverpool  University  Neuroleptic  Side  Effect  Rating  Scale  (LUNSERS),51 




difficulties  find  it  a  long  questionnaire  with many  questions  addressing  the  same 
clinical effect. Reducing the total number of items with in the range of other scales 
(about 30 items)51,53 would increase its feasibility for screening purposes. 
treatment of depressive symptoms
treatment guidelines  Antidepressants may  be  added  as  an  adjunct  to  anti-
psychotics when the depressive symptoms meet  the syndromal criteria  for major de-
pressive disorder or cause significant distress.28-30 But there is conflicting evidence on 





The most  common  distinction  between  antipsychotics  is  between  the  typical  (first 




prefer  second generation  antipsychotics  over  first  generation  antipsychotics  in  the 
treatment  of  patients  with  schizophrenia  and  co-morbid  depressive  symptoms,29,30 
although the evidence for this recommendation is poor.58 The guidelines provide no 
specific  recommendation  to  treat  or  prevent  depressive  symptoms  in  response  to 
antipsychotics.28-30  
depressive symptoms in response to antipsychotics  Antipsychotic 
treatment is thought to relief psychotic symptoms by making abnormal perceptions or 
delusional beliefs less meaningful and intense. Antipsychotics reduce the overactive 
dopaminergic  transmission  by  blockade  of  dopamine  receptors  in  striatal  brain 
areas.59 Blockade of dopamine D2 receptors  in non-striatal brain regions  (Figure 3) 
may, however, block emotional experiences.60,61 
Early  observations  of  antipsychotic-induced  depressive  symptoms  associated 
these  depressive  symptoms  with  parkinsonian  effects  of  dopaminergic  blockade 
in  the  nigrostriatal  pathways.25,62  Nowadays  patients  using  the  second  generation 
antipsychotics with a  lower risk of  these extrapyramidal side effects, still attribute 
depressive symptoms to antipsychotics.44-46 Animal research showed how dopamine 
D2 receptor  blockade  may  disturb  the  reward  system  in  other  brain  regions.
63,64 
The  resultant  experience  of  relative  anhedonia may  resemble  a  depressed  state.6 
Antipsychotics may affect brain regions involved in the pleasure of reward by blockade 
of  the dopaminergic pathways projecting  to  the nucleus accumbens and prefrontal 
cortex.65-68 Given that the dopamine transmission  in the prefrontal cortex  is already 
under-active  in  patients  with  schizophrenia,69,70  additional  dopaminergic  blockade 



























antipsychotics differ in d2 receptor affinity and occupancy
Antipsychotics  differ  in  their  binding  affinity  for  the  D2 receptor,
57,80  which  has 
implications  for  their  therapeutic  action  and  (emotional)  side  effects.  The  binding 
affinity  constant  (Kd)  reflects  the  concentration of  antipsychotic  required  to occupy 
50%  of  the  receptors  at  the  equilibrium  state  in  a  test  tube.  In  the  human  brain, 
however, the dynamic neurotransmission system does not allow these drug-receptor 
















as  the  dopamine  concentration  rises.  Antipsychotics with weak D2 receptor  affinity 
(quetiapine and clozapine) enable a quick response to instant changes in endogenous 
dopamine levels of the patient, for example an emotional response to a video game 






of  antipsychotics  with  weak  affinity  for  the  D2 receptor  give  a  transient  peak  level 
of  about  60%  D2 receptor  occupancy  in  the  brain,












antipsychotic  D2 receptors  affinity  and  its  occupancy  of  D2 receptors  in  the  brain. 
Generally, antipsychotics that dissociate faster from the D2 receptor than endogenous 




















study  groups, minimal  effect  sizes  and  no  control  group  using  antipsychotics with 
weak affinity for the D2 receptor.
75,77,78 
There  is  rising  interest  in meta-analysis  of  published  imaging  data,  which  can  be 
used  to  develop  dose-occupancy  equivalents  that  estimate  the  level  of D2 receptor 
occupancy  for  a  given  antipsychotic  dose.  Lataster  was  the  first  to  develop  dose-
occupancy  equivalents  that  predict  the  mean  level  of  occupancy  of  a  population 
based on antipsychotic dose.78 The dose-occupancy relationship has been described 
for antipsychotics with medium to high affinity  for the D2 receptor but not  for weak 
dopamine  antagonists  like  quetiapine.78  Furthermore,  previous  meta-analyses  did 
not take into account possible bias introduced by methodological differences between 
imaging  studies.88,89  The  three-dimensional  image  of  D2  receptor  occupancy  in  the 
brain  may  depend  on  the  imaging  technique  (Positron  Emission  Tomography  or 
Single Photon Emission Tomography) or  the choice of radioligand that binds  to  the 
D2 receptor.
90  The  effect  of  methodological  heterogeneity  on  the  relation  between 
antipsychotic dose and D2 receptor occupancy is increasingly relevant in view of the 
raising  interest  in clinical  implications of D2 receptor occupancy data.
78,88,91-94 Dose-
occupancy equivalents can be used  to compare D2 receptor mediated  (side) effects 











research aims and outline of the thesis
Goals  in  the  clinical  treatment  of  patients  with  schizophrenia  and  depressive 







The  second  aim  of  this  thesis  is  to  describe  the  relationship  between  depressive 
symptoms and D2 receptor affinity and occupancy.

















































monitoring  of  depressive  symptoms  in  patients  with  schizophrenia.  Depression 
instruments are compared on their psychometric properties, including the ability to 
discriminate  depressive  symptoms  from negative  psychotic  symptoms.  Chapters  4 
and 5 compare the validity of two self-report depression instruments with interview-
based assessments of depressive symptoms in patients with schizophrenia. 
Chapters  6  to  8  address  the  relationship  between  antipsychotics  and  depressive 
symptoms. Chapter 6  investigates whether patients attribute depressive symptoms 
to  their  antipsychotics  independent  from other  experiences  like  drug-induced EPS 




with  distinct  D2 receptor  affinities.  We  investigate  the  effects  of  methodological 
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disorders,  but  little  is  known  about  their  effects  in  routine  clinical  practice.  The 
objective was to investigate the prescribing patterns of antidepressants in relation to 
the course of depressive symptoms in patients with psychotic disorders. 
methods    A  cohort  of  214  Dutch  patients  with  psychotic  disorders  received  two 
assessments of somatic and psychiatric health, including a clinician-rated screening 
for depressive symptoms, as part of annual routine outcome monitoring. 





symptoms  at  baseline,  polypharmacy  was  a  potential  risk  factor  to  keep  having 
depressive symptoms  (OR  [95% CI] = 1.593  [1.1232.261]). Antidepressant use was 
not an independent predictor in both analyses.  






































Depressive  symptoms  occur  in  about  25%  of  patients  with  schizophrenia,1,2  but 
the  reported  prevalence may  vary  between  7%  and  75%.3-6  The  variation  is  due  to 
heterogeneous  study  populations,  differences  in  study methods  and  differences  in 
diagnostic criteria. Depressive symptoms may be present  throughout all phases of 
schizophrenia.6,7  The highest prevalence  is  found during acute psychotic episodes8. 
Persistent  depressive  symptoms  during  the  chronic  phase  of  illness  have  been 
associated  with  a  higher  risk  for  relapses.9,10  Depressive  symptoms  may  reflect 
a  psychological  reaction  to  the  severe  illness  or  ‘demoralization  syndrome’,11  or 
can  partly mimic  extrapyramidal  side  effects  related  to  the  dopamine  blockade  of 
antipsychotics,  known  as  ‘akinetic  depression’  or  dysphoria.5,12,13  Antipsychotic-
induced  depressive  symptoms may  be  treated  by  lowering  the  antipsychotic  dose, 
switching to another (atypical) antipsychotic or adding anticholinergic medication.2,14 
Guidelines for the treatment of schizophrenia advise prescribing antidepressants for 







Longitudinal  observational  studies  describing  predictors  for  the  development  or 




or  remain  untreated with  antidepressants.  The  current  naturalistic  study  is  based 
on a cohort of patients with schizophrenia or related psychotic disorders, assessed 
during yearly routine outcome measurements. The aim is to  investigate the course 







were  included  in yearly routine outcome assessments of  their physical and mental 
health as described previously.30,31 Assessments were carried out between January 
2003  and April  2006  in  patients  having  given  informed  consent  in  accordance with 
the  latest  version  of  the  Declaration  of  Helsinki.  Patients  were  included  if  they 
completed  a  first  (baseline)  and  second  assessment  (follow-up)  within  an  interval 
of 12 months  (±3 months).  In-patients with an acute psychosis at  first assessment 
were  excluded  from  analysis.  Trained  nurses  conducted  a  structured  interview 




(DSM-IV)  classification  system  (codes  295.4  -  295.9,  297.1,  298.8  and  298.9).32  The 





who  did  not  have  depressive  symptoms  at  both  assessments  and  patients  who 
developed  depressive  symptoms  at  second  assessment  (‘incidence’);  b)  between 
patients with depressive symptoms at baseline that were no longer present at second 









at  follow-up. Only  those baseline characteristics with a  significance  level  of p<0.25 














































A  total  of  473  patients  were  eligible  for  inclusion  into  the  study.  Of  those,  34% 
(162)  did  not  want  to  participate  in  a  second  assessment  or  were  lost  to  follow-
up,  e.g.  moved  away.  21%  (97)  patients  had  their  second  assessment  not 




from schizophrenia  and  the majority was  outpatient  (Table  1). Patients  included  in 
the study did not differ  from the 259 not-included patients regarding age, duration 
of  illness  and  prevalence  of  depressive  symptoms  at  baseline.  The  proportion  of 
females and outpatients was somewhat higher in the group of included patients, as 
was  the proportion of patients using antidepressants and  the average GAF-scores. 












Gender, female (%; N) 43% (92) 34% (88) χ2 = 4.04 0.044
Age (mean; SD) 38.7 (11.7) 39.6 (12.6) Z = -1.14 0.255
Duration of illness (mean; SD) 12.2 (9.4) 11.1 (9.8) Z = -1.25 0.211









GAF-Symptoms 65.6 (15.1) 59.0 (18.5) Z = -5.02 0.000
GAF-Disability  61.0 (16.0) 56.4 (16.4) Z = -4.22 0.000
Depressive symptoms (%; N) 43% (93) 37% (97) χ2 = 1.76 0.185
Antidepressants (%; N) 40% (86) 27% (69) χ2 = 8.89 0.003
N=number;  SD=standard  deviation;  NOS=  Not  Otherwise  Specified;  GAF=Global  Assessment  of 












































Gender, female (%; N) 46% (62) 38% (30) χ2 = 1.03 0.311
Age (mean; SD) 38.4 (12.2) 39.4 (11.0) Z = -0.69 0.489
Duration of illness (mean; SD) 11.6 (9.6) 13.3 (8.9) Z = -1.63 0.103









No daytime activities 29% (36) 24% (18) χ2 = 0.58 0.447
No contact with friends 31% (42) 21% (16) χ2 = 2.70 0.100
No contact with family 12% (16) 6% (5) χ2 = 1.61 0.205
Symptomatology (mean; SD)
GAF-Symptoms 66.9 (15.9) 63.4 (13.2) Z = -1.58 0.113
GAF-Disability 61.3 (16.9) 60.4 (14.3) Z = -0.75 0.454
Extrapyramidal symptoms (%; N)  15% (20) 18% (14) χ2 = 0.39 0.532
Depressive symptoms  29% (40) 68% (53) χ2 = 29.96 0.000





Number of drugs prescribed (mean; SD) 2.4 (1.6) 3.3 (2.3) Z = -2.81 0.005
Number of drugs prescribed; excl.antidepr. 2.0 (1.4) 2.8 (2.2) Z = -2.41 0.016
Antidepressants (%; N)  35% (47) 50% (39) χ2 = 4.92 0.027
Anticholinergics  4% (5) 9% (7) χ2 = 2.63 0.105
Benzodiazepines  32% (43) 40% (31) χ2 = 1.45 0.229
Moodstabilizers  13% (17) 14% (11) χ2 = 0.11 0.738












associated with  the  following baseline characteristics with a p-value  < 0.25: duration 











=  0.953  [0.912-0.995],  p<0.030),  when  adjusting  for  the  subset  of  clinical  and  socio-
demographic characteristics as mentioned above. Of  the 93 patients with depressive 





























































antidepressants 42 no depressive symptoms 32 discontinued 7
incidence of depressive symptoms 10 discontinued 1
no antidepressants 79 no depressive symptoms 64 started 5
incidence of depressive symptoms 15 started 4
Depressive symptoms
antidepressants 44 remitted from depressive symptoms 15 discontinued 4
persistent depressive symptoms 29 discontinued 3
no antidepressants 49 remitted from depressive symptoms 25 started 4












studies.22,28  Previous  cross-sectional  studies  have  shown  that  depressive  symptoms 











Antidepressants  were  frequently  prescribed  in  routine  clinical  practice  as  in 
previous  studies.3,28,36,42  Our  study  brought  new  insight  into  the  prescribing  patterns 
of  antidepressants  in  relation  to  the  course  of  depressive  symptoms.  The  majority 




they  remained  free of depressive symptoms both  years. Their antidepressant  therapy 
may have served as an effective prophylaxis,43,44 for other indications such as negative 







prescription  of  antidepressants  to  the  depression  guideline,15  although  it  is  doubtful 






































of  antidepressants  is needed  for  the development and  improvement of  guidelines  for 
prescription of antidepressants in schizophrenia. 








such  as  psychotherapy  in  patients  without  antidepressants.  Secondly,  depressive 
symptoms  were  clinician-rated  instead  of  by  a  depression  instrument  validated 
for  schizophrenia.  We  therefore  cannot  be  sure  whether  the  clinicians  adequately 
distinguished depressive symptoms from negative symptoms. Thirdly, long-term follow-
up is considered difficult in patients with schizophrenia,22,46 but we achieved a reasonable 
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for  use  in  depressed  patients  may  not  discriminate  depressive  symptoms  from 
negative psychotic symptoms. We reviewed depression instruments on their reliability 
and validity in patients with schizophrenia. 




results    Forty-eight  publications  described  the  reliability  and  validity  of  six 
depression  instruments  in  patients  with  schizophrenia.  The  only  self-report  was 
the Beck Depression Inventory (BDI). The Brief Psychiatric Rating Scale-Depression 
subscale  (BPRS-D),  Positive  And  Negative  Syndrome  Scale-Depression  subscale 
(PANSS-D),  Hamilton  rating  scale  for  Depression  (HAMD),  Montgomery  Asberg 
Depression Rating Scale  (MADRS) and Calgary Depression Scale  for Schizophrenia 
(CDSS) were clinician rated. All  instruments were reliable  for  the measurement of 
depressive  symptoms  in  patients  with  schizophrenia.  The  CDSS  most  accurately 
differentiated depressive symptoms from other symptoms of schizophrenia (divergent 
validity), correlated well with other depression instruments (concurrent validity), and 
was  least  likely  to miss cases of depression or misdiagnose depression  (predictive 
validity). 
conclusions    We  would  recommend  to  use  the  CDSS  for  the  measurement 






















































Depressive  symptoms  are  highly  prevalent  (25%)  in  patients  with  schizophrenia.1,2 
These comorbid depressive symptoms are associated with a higher burden of disease 
and  more  frequent  relapses.3-5  Schizophrenia  is  a  lifelong  psychiatric  disorder 






instead  of  solely  as  discontinuous  categories  (http://www.dsm5.org).  Adequate 
screening and monitoring of depressive symptoms is required to guide appropriate 
treatment.10-12.
Measurement  instruments  can  be  helpful  for  screening  and  for  monitoring  of 
symptomatic  changes.13  The  assessment  of  depressive  symptoms  is  complicated 
in  patients  with  psychotic  disorders,  as  they  resemble  ‘classic’  symptoms  of 
schizophrenia, such as negative symptoms and extrapyramidal symptoms (EPS).1,14-
16  Particularly  drug-induced  parkinsonism may  resemble  a  depressed  state.17  It  is 
doubtful whether instruments, primarily developed for use among depressed patients, 













search procedure As  a  first  step,  titles  and  abstracts  were  screened  on 
relevance  for  the  defined  topic  and,  if  appropriate,  the  full  paper  was  examined. 
Inclusion criteria were: 1) studies assessing psychometric properties of instruments 







the addition of  [-D] to the abbreviation of the  instrument,  for example BPRS-D. We 
excluded  studies  describing  diagnostic  instruments  and  instruments  designed  to 
measure related symptoms, such as anxiety or suicidality. 
The following search terms were entered in the online databases PubMed, EMBASE 
and  PSYCHINFO:  ((“depression”  or  “depressive  symptoms”)  AND  (“schizophrenia” 
OR “psychosis” OR “psychotic”) AND (“instrument” OR “rating scale” OR “scale” OR 
“questionnaire” OR “interview”) AND (“psychometric” OR “reliability” OR “validation” 
OR  “validity”  OR  “reproducibility”)).  The  search  was  carried  out  in  May  2010.  All 
retrieved studies were checked for cross-references. 










dimensions  of  schizophrenia,  in  particular  negative  symptoms  and  extrapyramidal 
symptoms.  For  each  instrument,  the  number  of  potentially  overlapping  items was 




















































Psychometric  properties were  extracted  for  those  instruments  of which  reliability, 
divergent, concurrent and predictive validity were reported in one or more publications. 
In the next paragraphs we explain these psychometric properties. 




reliability  is  reflected by  little variation between  the scores by different  raters and, 
respectively,  by  repeated measurements;  these  are  commonly  expressed by  Intra-
Class Coefficients (ICC) > 0.70. 
divergent validity    Divergent (or discriminant) validity refers to the extent that 
different  symptom  dimensions  are  unrelated  to  each  other.  Here,  an  instrument 
designed to measure depressive symptoms, should not measure negative symptoms, 






Divergent  validity  can  also  be  evaluated  on  the  stability  of  the  underlying  factor 
structure of a particular instrument across different samples. For multidimensional 
instruments, Principal Component  factor Analysis  (PCA) should  identify depressive 
symptoms  as  a  separate  factor  from  psychotic  symptom  dimensions.  In  addition, 







concurrent validity    Concurrent  (or  convergent)  validity  refers  to  the  extent 
that common symptom dimensions are in fact related. Concurrent validity is high when 




predictive validity    Predictive validity represents the accuracy of an instrument 
to  correctly detect a  case  (here of depression).  Included were publications using a 
validated diagnostic  interview such as  the Structured Clinical  Interview  for DSM-IV 
as gold standard to identify positive cases of depression.24 Good predictive validity is 
reflected by high sensitivity  (not  likely  to miss cases of depression)  combined with 















































































For  six  depression  instruments  complete  information  on  psychometric  properties 
in  a  population  with  schizophrenia  or  psychotic  disorders  was  described  in  49 
publications. These included two multidimensional instruments: the Brief Psychiatric 
Rating Scale, Expanded Version (BPRS),26,27 and the Positive And Negative Syndrome 
Scale  (PANSS),28  and  four  unidimensional  instruments:  the  Hamilton  Rating  Scale 
for Depression  (HAMD),29 Montgomery Asberg Depression Rating  Scale  (MADRS),30 




with  incomplete  information  about  their  psychometric  properties  in  schizophrenia. 
For  example,  no  information  was  available  on  reliability  or  divergent  validity  in 
schizophrenia for the Brief Symptom Inventory (BSI),33 and Center for Epidemiologic 
Studies Depression Scale (CES-D).34 
general characteristics    General characteristics of the six reviewed depres-


















BPRS multidimensional clin.r. ++ 25-40 2 weeks 24 7   3
PANSS multidimensional clin.r. +++ 30-40 1 week 30 7   6
HAMD unidimensional clin.r. + 20 3 days 17 5   5
MADRS unidimensional clin.r. + 15 1 week 10 4   1
CDSS unidimensional clin.r. ++  15-20 2 weeks 9 4   6
BDI unidimensional self-r. n.a. 10 2 weeks 21 4   4



























































Table 2  illustrates  the composition of  the depression  instruments  in  the context of 
schizophrenia. The depressive symptoms covered by the CDSS had minimal overlap 









































depressed mood a 1 1 1 1 3 4 4
changed appetite or weight 1 - - 2 1 - 1
sleeping problems 1 - - 3 1 1 1
worthlessness b 1 - - - - 2 4
suicidal ideation 1 1 - 1 1 1 1
negative 
symptoms
loss of interest or pleasure 1 - - - 1 - 2
fatigue / lack of initiative or motivation  1 - - 1 1 - 2
indecisiveness / lack of concentration  1 - - - 1 - 2
EPS psychomotor agitation or retardation 1 - - 2 - - 1
other
delusional ideas c - 3 2 3 - 1 2
other vital symptoms d - - - 2 - - 1




4 4 4 10 4 1 10
9 6 5 17 10 9 21
% of items identifying non-depressive dimensions 44% 67% 80% 59% 40% 11% 48%
Depressive  symptoms  (dimensions)  potentially  overlapping with  psychotic  symptoms.  a)  Appeared 
or  perceived  depressed mood,  including  hopelessness,  crying,  pessimism,  irritability  and  diurnal 
variation of mood. b) Including self-blame and non-delusional feelings of guilt. c) Including paranoid 

















The  underlying  factor  structure  of  the  multidimensional  instruments  (BPRS  and 
PANSS) generally consisted of one factor for depression and two to four other factors. 







concurrent validity    The  concurrent  validity  of  the  depression  instruments 






























































       a. reliability
  Internal consistency  Inter-rater  Test-retest  References
BPRS-D 0.67 0.74 0.72 [31,36]
PANSS-D 0.77 0.80 - [37,38]
HAMD 0.75 (0.73 - 0.77) 0.94 (0.93 - 0.95) 0.75 (0.65 - 0.80) [31,36,39-41]
MADRS 0.91 0.81 0.71 [37,41,42]
CDSS 0.82 (0.76 - 0.88) 0.86 (0.73 - 0.98) 0.83 (0.69 - 0.93) [31,39-41,43-52]
BDI 0.90 (0.88 - 0.91) n.a.  - [31,53]
       b. divergent validity
  Negative symptoms References EPS References
BPRS-D 0.00 (-0.11  0.10) [36,54,55] 0.14 (0.07 - 0.21) [56,57]
PANSS-D 0.19 (-0.11  0.41) [19,37,49,55,58-60] 0.07 (0.01 - 0.20) [19,56,58,59]
HAM-D 0.18 ( 0.02  0.45) [36,49,55,57-64] 0.40 (0.02 - 0.79) [48,56-59]
MADRS 0.36 ( 0.12  0.51) [19,37,49,57] 0.52 (0.16 - 0.86) [19,48,57]
CDSS 0.10 (-0.24  0.54) [43,45-49,55,57-60,65,66] 0.26 (0.07 - 0.42) [43,45,47,48,56-59,65,66]
BDI 0.10 (-0.11  0.21) [53,59,64,67] 0.23 [59]


























BPRS-D 0.23 0.66 0.66 0.79 0.64 0.60 (0.17 - 0.87) [31,36,39,55,57,61,68,69]
PANSS-D 0.62 0.72 0.66 0.49 0.54 (0.17 - 0.87) [19,37,41,43,45,47,49,53, 55,58-60,69]
HAMD 0.80 0.74 0.57 0.68 (0.26 - 0.90) [31,36,39,41,42,45,47-49, 55,57-61,63,64,67,70]
MADRS 0.81 - 0.75 (0.56 - 0.90) [19,37,41,42,45,48,49,57]






Sensitivity Specificity Cut-off value References
BPRS-D - - - -
PANSS-D 78% (74- 81%) 85% (79-90%) ≥ 5; ≥ 10 [49,59]
HAMD 79% (67- 91%) 83% (81-84%) ≥ 12 [49,59]
MADRS 81% 81% ≥ 11 [49]
CDSS 88% (67-100%) 88% (74-97%) ≥ 5; ≥ 6; ≥ 9 [31,43,45,49,59]



























































summary of results    We  identified  five  clinician-rated  instruments  and  only 
one self-report with tested reliability and validity for the measurement of depressive 
symptoms in patients with schizophrenia. 
reliability    The  reliability  of  the  reviewed  depression  instruments  was  good 
in  populations  with  schizophrenia  and  comparable  to  populations  with  depressed 
patients  or  healthy  subjects.20,86  In  other  words,  patients  with  schizophrenia  can 
reliably be assessed on the presence of depressive symptoms by  interview or self-
report. 
validity    The  instruments  differed  in  their  accuracy  to  distinguish  depressive 
symptoms  from  other  symptoms  of  schizophrenia  (divergent  validity).  Correlation 
studies and factor analysis showed that the CDSS measures nearly no other symptoms 
of  schizophrenia.  Inspection  of  the  items  of  the  CDSS  supported  that  the  overlap 
with  negative  symptoms  or  EPS  was  minimal  compared  to  the  other  depression 
instruments. The high divergent validity of the CDSS is in line with the fact that this 
instrument has especially been developed  for  this population.31 For example,  “lack 





This  wide  variation  of  symptom  dimensions  covered  by  the  reviewed  instruments 
may  explain  the modest  inter-correlations  between most  depression  instruments. 
The low concurrent validity between instruments may even be over-estimated by the 
halo-effect. Ideally raters are not influenced by knowledge of the subject’s scores on 
other  instruments.89 However,  in some studies multiple  instruments for depressive 
symptoms were rated by a single rater,57 or  the distribution of  tasks among raters 
was unclear.59,60 







we  included only  those studies with standardized procedures  to obtain  the optimal 
cut-off value (Area Under the Curve methods). 
practical considerations    Practical issues such as time investment may also 
be  important  when  choosing  an  instrument,  apart  from  the  psychometric  aspects 
discussed above. The amount of  training and time to complete the  interview of  the 
CDSS was comparable to the HAMD and MADRS. In contrast, the multidimensional 
instruments  BPRS  and  PANSS may  need more  time  and  training  to  complete  the 
interview, although an advantage may be  that besides depressive symptoms, other 
psychotic symptoms can be evaluated at the same time. 
future research    An important finding was the lack of self-report instruments 
for the measurement of depressive symptoms in this population. The concurrent and 
predictive validity of the only reviewed self-report here BDI was rather poor. Especially 




provide more  independent  information on  the patients’ experience of depression  in 
schizophrenia  than  interview-based assessments.69 The  literature search  identified 
several  other  self-report  questionnaires  for  depressive  symptoms,  such  as  the 
CES-D  and  the BSI  (a  short  version  of  the  Symptom Checklist-90).33  Evaluation  of 
the composition of the BSI showed that only one of the six  items of the depression 
subscale  had  potential  overlap  with  negative  symptoms  [data  not  shown].  Future 
research is needed to develop and validate a self-report comparable to the CDSS with 
respect to reliability and validity in schizophrenia. 
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results    In  a  sample  of  621  patients  with  psychotic  disorders,  the  QIDS-SR16 










































Depressive  symptoms  are  highly  prevalent  in  patients  with  schizophrenia,  with 





as  drug-induced  parkinsonism.8  Therefore,  monitoring  depressive  symptoms 
requires  reliable  instruments with  tested  validity  in  patients with  schizophrenia. 
To date, the only instrument designed for the assessment of depressive symptoms 
in  this  patient  population  is  the  interview-based  Calgary  Depression  Scale  for 





saves  time  and  costs  in  routine  clinical  practice.11  The  availability  of  self-report 





found  that  the  presence  of  psychotic  symptoms  did  not meaningfully  affect  the 




extrapyramidal  symptoms  in  this  population  (divergent  validity).  Furthermore, 
it  is  unknown  whether  the  latent  structure  of  the  QIDS-SR16  remains  one-
dimensional,16,17 or that multiple (negative symptom) dimensions can be identified 
when applied in patients with schizophrenia. 
The  aim  of  the  current  study  is  to  evaluate  the  psychometric  properties  of  the 
QIDS-SR16  in a population of patients with psychotic disorders. We examined  (1) 











consent  in  accordance with  the  committee’s  guidelines.  For  a  detailed  overview of 
the GROUP structure, data flow, quality control, recruitment, sample characteristics 
of the studied patients and training procedures of the assessors, see Korver (2012).18 
The  current  data was  collected  during  the  second  assessment  of  the  study,  three 




Schizophrenia  (CDSS),  Positive  and  Negative  Syndrome  Scale  (PANSS),  Abnormal 
and Involuntary Movements Scale (AIMS) and Barnes Akathisia Rating Scale (BARS). 
These rating scales were administered by trained research assistants. 




3, with a  total  score  range of 027. For an  interpretation  the QIDS-SR16 total  score 
see http://www.ids-qids.org. Depressive symptoms were also assessed by the 9-item 
CDSS interview.9 Item scores are rated on a Likert scale ranging from 0 to 3. A sum 
score  above  4  out  of  27  on  the  CDSS was  used  as  cut-off  scores  to  establish  the 
presence of a minor depressive episode or clinical depression.9,20 Psychotic symptoms 
were assessed with the PANSS.21,22 For the current analyses, we used the five-factor 
model  of  the  PANSS,23  consisting  of  the  subscales  ‘positive  symptoms’,  ‘negative 
symptoms’, ‘disorganization symptoms’, ‘excitement’ and  ‘emotional distress’. Item 
scores  of  the PANSS  range  from 1  (not  present)  to  7  (extreme)  and  the  subscales 







































statistical analyses    Psychometric properties of the QIDS-SR16 were examined 
using SPSS, version 16.0. The reliability of the QIDS-SR16 was assessed by calculating 
Cronbach’s  alpha  as  a measure  for  internal  consistency. A  value  of  0.80  or  higher 




























reliability and dimensionality    The  QIDS-SR16  showed  good  internal 













Ad  Table  1:  Abbreviations:  SD,  Standard  Deviation;  QIDS-SR16,  Quick  Inventory  of  Depressive 
Symptomatology  16-item  self-report  version;  CDSS,  Calgary  Depression  Scale  for  Schizophrenia; 
PANSS, Positive and Negative Syndrome Scale; AIMS, Abnormal Involuntary Movement Scale; BARS, 































































































































concurrent and divergent validity    The  correlations  of  the  individual 
domains of the QIDS-SR16 with the CDSS ranged between 0.14 and 0.46 (Table 2). The 
total  score  of  the QIDS-SR16  correlated moderately with  the CDSS  (ρ=0.44; p<.001) 
and the PANSS subscale for emotional distress (ρ=0.47; p<.001), as displayed in Table 
3.  The QIDS-SR16  showed weak  correlations with  negative  symptom  ratings  of  the 




















PANSS-D 0.47*** 0.59*** 1
Divergent validity PANSS-N  0.28*** 0.34*** 0.40***
AIMS 0.09* 0.06 0.06
BARS 0.16*** 0.09* 0.15***
UPDRS-motor 0.10* 0.17*** 0.21***
Significant  correlations were  indicated  by  ***=  p  <.001;  **=  p  <.01;  *=  p<.05.  Abbreviations:  QIDS-SR16, 
Quick  Inventory of Depressive Symptoms 16-item self-report version; CDSS, Calgary Depression Scale 
for Schizophrenia; PANSS, Positive and Negative Syndrome Scale, emotional distress subscale (-D) and 




































The  current  study  was,  to  the  best  of  our  knowledge,  the  first  to  investigate  the 
psychometric properties of the QIDS-SR16 in a large sample of patients with psychotic 
disorders.  The  QIDS-SR16  remained  unidimensional  in  the  current  sample.
16,17 














of  depression.19  Indeed,  post  hoc  analysis  demonstrated  that  those  patients  using 
antipsychotics with high antagonistic affinity for the histamine receptor (olanzapine 
or  clozapine)  reported  higher  scores  on  excessive  sleep  than  patients  using  other 
antipsychotics  (OR  [95%CI]  =  1.88  [1.31-2.68];  data  not  shown).  Similarly,  patients 








may  be  prone  to  psychological  depressive  symptoms  like  hopelessness  and  self-
depreciation,  possibly  related  to  demoralization  in  response  to  the  severe mental 







from negative  symptoms  in  an acceptable way,  in  line with previous work on  the  full 
30-item Inventory of Depressive Symptoms (IDS) in a mixed population of patients with 
schizophrenia and bipolar disorder.35,36 In addition, a latent factor for negative symptoms 





An  unexpected  result  is  the  relatively  high  correlation  of  the  CDSS  with  negative 
symptoms  in  comparison  to  previous  reports  of  the  CDSS  in  patients  with 
schizophrenia.12 Though some correlation with negative symptoms is acceptable, as 
patients may often experience both negative and depressive symptoms at the same 
time.37 Another caveat when  interpreting  the current results  is  that  the majority of 
the patients had  low EPS  ratings. The  relatively  young and possibly well  stabilized 
sample of patients may explain the rare presence of EPS, as previously described for 
the baseline measurement of the current sample.38 We therefore remain inconclusive 
about  the  divergent  validity  of  the  QIDS-SR16  with  respect  to  the  extrapyramidal 
symptoms in this population. 







To  conclude,  we  showed  that  patients  with  a  psychotic  disorder  can  reliably  rate 
their  depressive  symptoms  by  means  of  the  self-report.  However,  based  on  the 
poor concurrent validity of the QIDS-SR16 with the CDSS, the gold standard for rating 
depression  in  patients  with  schizophrenia,  we would  not  recommend  applying  the 
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objective    We  aimed  to  test  the  concurrent  validity  between  the  self-reported 
CES-D  and  the  Calgary  Depression  Scale  for  Schizophrenia  (CDSS)  interview  in 
patients with schizophrenia. 






conclusions    Self-rating  of  depression  by  means  of  the  CES-D  seems  to  be 























































and  routine  monitoring  of  these  symptoms  may  guide  appropriate  treatment.4,5 
Depressive symptoms are difficult to distinguish from negative psychotic symptoms 
and other symptoms of schizophrenia,  requiring  instruments with  tested validity  in 
patients with schizophrenia. To date, the only instrument designed for the assessment 
of  depressive  symptoms  in  this  patient  population  is  the  interview-based  Calgary 
Depression Scale  for Schizophrenia  (CDSS).6 Self-report  in  routine clinical practice 





(BDI)9  is  the only self-report  instrument  for depressive symptoms of which several 
aspects of  reliability and validity have been  tested  in patients with schizophrenia.10 





















This  cross-sectional  study  was  carried  out  between  February  2010-2011  in  the 
department of psychotic disorders of a mental health care organization in the North 






the  20-item  CES-D  questionnaire,  prior  to  the  nine-item  semi-structured  CDSS 
interview by a trained nurse. A psychiatrist assessed psychosocial functioning using 
the Global Assessment of Functioning scales  (GAF-Symptoms and GAF-Disability)17 









The  level  of  agreement  between  depression  instruments  was  expressed  by  the 
Spearman’s rank correlation coefficient. As a measure of reliability, we determined the 
internal consistency by the Cronbach’s alpha (α) for each questionnaire. The internal 





















































patients  refused  the  CDSS  interview  and  one  patient  did  not  complete  the  CES-D 
questionnaire. So a  total of 122 patients were  included  in  the study. The mean age 
was 41.1 years (SD 11.0; range 18-66 years) and 67% (n=82) were male patients. The 
mean GAF-score was  60.0  (SD  14.5)  for  symptoms  and  respectively  60.3  (SD  12.9) 
for  disability.  Antidepressants  were  prescribed  for  33%  (n=40)  of  the  patients  and 
mood stabilizers  for  5%  (n=6)  in  addition  to  their  antipsychotic  treatment. Of note, 
information on patient status, GAF, HoNOS and current medication use was lacking 
for 14 patients. Clinical depression was present among 37.7% (n=46) of the patients 
according  to  the CES-D and 9.8%  (n=12) according  to  the CDSS, of which 11 cases 
were also detected by the CES-D. 
The  CES-D  correlated with  individual  items  of  the  CDSS  between  0.197  and  0.527 
(Table 1). The correlation coefficient between the total scores of the CES-D and the 
CDSS was 0.703 (p<0.01). The correlation of the CES-D and CDSS with the depression 















of  the Diagnostic and Statistical Manual of Mental Disorders  (DSM-5) advocates  to 
measure psychopathology in terms of quantitative dimensions, rather than solely as 






(correlation  coefficients  r>0.70).6,27,28  In  the  current  study,  we  noticed  that  patients 
experienced minimal effort to complete the CES-D questionnaire, implying that this 
self-report  instrument  is  feasible  in a population with schizophrenia. Furthermore, 
the  relatively  poor  congruency  of  both  the  CES-D  and  CDSS  with  the  HoNOS-
depression item indicated that a single observed-rated depression item of a general 





the  CES-D  was  primarily  developed  to  monitor  sub-clinical  depressive  symptoms 
rather  than detecting cases of depression. Another  reason  for  the high prevalence 
rate could be that the cut-off score of the CES-D to detect cases of depression was 
not optimal for the current population. For example, the prevalence of potential cases 






















































schizophrenia.  We  therefore  recommend  careful  interpretation  of  positive  CES-D 
scores  and  confirm  the  diagnosis  of  depression  in  patients  with  persistently  high 
scores by a diagnostic interview.
The current study demonstrated that the CES-D is a feasible self-report instrument 
for  the  monitoring  of  depressive  symptoms  in  routine  clinical  practice  with  high 
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methods    Included  were  patients  with  psychotic  disorders  from  seven  mental 
health  care  organizations  in  the Netherlands,  using  antipsychotic medication, who 
completed  the  Subjects’  Response  to  Antipsychotics  (SRA-74).  Exploratory  factor 
analysis  (EFA)  and  similarity  analysis  based  on  mutual  information  were  used  to 
identify the latent factor structure of the SRA. Items were reduced according to their 
metric properties and clinical  relevance upon consensus by an expert panel, using 













































Schizophrenia  is  a  chronic  psychiatric  disease,  commonly  necessitating  lifelong 
treatment with antipsychotics. Antipsychotics increase the burden of disease, when 
they  affect  patients’  physical,  psychological,  sexual  and  social  functioning.1  The 
patients’  experience  of  desired  and  undesired  effects  in  response  to  antipsychotic 
medication has  been  identified  as  a  strong predictor  of  adherence  and  outcome.2,3 
Systematic monitoring  of  the  balance  between  desired  and  undesired  effects with 
antipsychotics  is  important for disease management.4,5 This requires a reliable and 
valid instrument. 




(SWN)8  or  undesired  effects  only,  like  the  Liverpool  University  Neuroleptic  Side 
Effect  Rating  Scale  (LUNSERS)9  and  the  Glasgow  Antipsychotic    Side-effect  Scale 
(GASS),10 see Wolters.11  In contrast,  the Subjects’ Response to Antipsychotics  (SRA) 
is  a  comprehensive  assessment  of  74  desired  and  undesired  effects  attributed  to 


















(Chronbach’s  alpha  0.69-0.93)  and  test-retest  reliability  (Pearson’s  r  correlation 
0.39-0.60). The SRA is rated on a 3-point scale (not present / yes, mild / yes, severe). 









subjects    Patients with  psychotic  disorders  receiving mental  health  care  in  the 
North of  the Netherlands, Amsterdam and Dordrecht were  invited  to participate  in 





SRA  (maximally  2  items missing).  In  case  a  patient  had  participated  in  successive 
annual assessments, the first available measurement was selected for evaluation. 




























































delphi procedure    A  Delphi  procedure  consisting  of  three  consecutive 
rounds  was  used  to  reach  consensus  about  the  clinical  relevance  of  the  items  in 
the  questionnaire.22  The  expert  panel,  all  native  Dutch  speaking,  consisted  of  six 
psychiatrists,  two  neurobiologists  and  two  psychologists.  In  the  first  round,  the 
panelists received the full questionnaire including the results of the statistical analysis 
by e-mail. The experts were asked 1) to rank order the clinical relevance of the non-
factorable  items  dropped  for  statistical  reasons  and  2)  to  mark  redundant  items 








including  a  summary  of  the  arguments  for  item  elimination  or  preservation.  The 





statistics    Descriptive  analyses  and  factor  analysis  were  performed  using 
Statistical  Package  for  Social  Sciences  (PASW-18).  Patient  characteristics  were 
compared between samples by Chi-Square tests for categorical variables and Mann-
Whitney U tests for continuous variables. Missing SRA-responses were imputed for 








retained was  predefined  by  the  Kaisers  criterion  (eigenvalues ≥  1).  Kaiser-Meyer-





logarithms  (the  in-home created script  is available on request) and visualized by a 
73x73 similarity matrix. Items were grouped according to the factors from the EFA.



































subjects    The number of patients  included  for evaluation was n=1478  (66%) out of 
n=2241  patients  with  psychotic  disorders  receiving  routine  outcome  assessments  in 
the selected mental health care organizations between 2006 and 2010. Excluded were 








to 18  (38%) out of 50 undesired effects. Patients most  frequently reported  the desired 












































item reduction    The number  of  items of  the  questionnaire was  reduced  to  52 






clearly’.  Similarly,  the  statements #16  ‘I  think more slowly’  and #50  ‘I move more 
slowly’ were considered redundant  to #13  ‘I  react more slowly’. Some of  the  items 
were eliminated because they may be stigmatizing or evoke socially desired answers, 





internal consistency of sra-34    The internal consistency was acceptable 



































74  Total number of SRA items         
  -23  Eliminated non-factorable items (exploratory factor analysis)
    12  All loadings <0.3
    2  Cross-loadings of >0.30
    8  Main factor loading <0.50 
    1  Responded by females only
    11  Retained non-factorable items because of clinical relevance (expert panel)
  -28  Eliminated factorable items considered redundant (expert panel)
      14  ambiguous content
      7  non-specific content 
      4  evoking socially desired responses 
      3  dependent on external factors 
                 
34  Number of items of shorter version of SRA           
 
AD  FIGURE  2  (p.97).  Similarity  matrix,  comparing  the  amount  of  mutual  information  shared 
between all 73 SRA-items (n=1478). All SRA-items on the x- and y-axis were listed according to the 














1. Appetite 19. I have an increased appetite 1.098 49%
    32. I am hungry more often 0.689 47%




    65. I have more trouble concentrating 0.329 42%








    30. I am less irritable <0.30 85%
4. Weight Gain 46. I have gained too much weight -0.958 55%
    60. My weight has increased -0.898 60%
66. I am less fit <0.30 48%




    62. I feel physically healthier -0.377 88%
6. Sexual Problems 70. My sex drive is too low -0.884 31%
17. My sex drive has decreased -0.791 42%
    55. It is more difficult for me to have an orgasm -0.715 28%














































    67. I have a dry mouth more often <0.30 36%






    73. I am more detached <0.30 30%





    22. I am less creative <0.30 40%
11. Recovery 49. I am less psychotic 0.652 60%
Psychosis 52. I hear fewer voices 0.458 73%
    18. I am less anxious 0.307 80%






    38. My sex drive has increased <0.30 9%







    47. I perspire more <0.30 33%




    31. I get psychotic symptoms <0.30 11%




APPENDIX  1.    The  SRA-34  questionnaire  in  random  order,  divided  into  nine  subscales  for 






















































































































































































































































































































The  SRA-34  is  a  unique  questionnaire  to measure  a  combination  of  relevant  self-
reported  desired  and  undesired  effects  in  response  to  antipsychotic  medication. 
This  is the short version of  the SRA-74 questionnaire retaining the latent structure 
by  covering  10  desired  and  24  undesired  effects  of  antipsychotics.  The  SRA-34 




Exploratory  factor  analysis  of  the  SRA-74  revealed  new  symptom  dimensions,  in 
addition  to  the  original  subscale  structure  as  proposed  by  Wolters  (2006).12  First, 
desired effects were divided into four factors (recovery from psychosis, improvement 
in  cognition,  attention  and  social  functioning).  Second,  we  identified  depressive 
symptoms as a factor, independent of other emotional experiences. The other factors 















switching  antipsychotics  in  daily  clinical  practice  or  clinical  trials.  Completing  the 
SRA-34 should take a patient on average 5-10 minutes, about half the time needed 












































bias  in  our  analysis.  Another  possible  limitation  of  the  study  was  that  we  applied 
exploratory  factor  analysis  to  a  three-point  scale  (SRA-74), which  could  lead  to  an 
overestimation of  the number of  factors.24 We minimized  this  risk by  selecting  the 
Generalized Least Squares method of EFA. Furthermore,  the  visual  representation 
of the latent structure (by means of similarity analysis based on mutual information) 
enabled us to detect artificial correlations. 
In  the  clinical  situation,  the  SRA-34  can  be  used  to  discuss  the  balance  between 
desired and undesired of antipsychotics with the patient. In line with previous studies, 
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Estimating dopamine D2 receptor occupancy for doses of 
eight antipsychotics. A meta-analysis.
104
7.0|  ABSTRACT 
rationale    Dose-equivalents  based  on  dopamine  D2  receptor  occupancy  can 
be  used  to  compare  antipsychotics  on D2  receptor mediated  (side)  effects  such  as 
extrapyramidal  symptoms  and  altered  emotional  experiences.  Previous  meta-
analyses  modeling  the  dose-occupancy  relationship  hardly  addressed  potential 
heterogeneity of the imaging data.  
objectives    To model  the  relationship between dose and D2  receptor occupancy 






study  as  a  random  effect  in  the  model,  in  addition  to  patient  and  study  specific 
explanatory variables. 
results    Included were 51 studies, describing N=606 patients (mean age 32.2 (±10.8) 




49.1%  [18.7;79.6],  aripiprazole  86.9%  [78.2;95.7],  ziprasidone  82.9%  [44.9;100]  and 















































Imaging  studies  suggest  that  effective  relief  of  psychotic  symptoms  is  associated 
with blockade of at  least 65% of striatal D2 receptors, but some antipsychotics can 










analysis  and  clinical  implications  of  D2  receptor  occupancy  data  is  growing.
10,12-15,16 






occupancy  for  some  antipsychotics  with  weak  affinity  for  the  dopamine  receptor; 
however these estimates were based on plasma levels and not on dose.13 Since plasma 
levels  of  antipsychotics  are  infrequently  determined  in  clinical  practice,  estimates 
based on antipsychotic dose may be more useful for epidemiological research. 
We aim to estimate D2 receptor occupancy in relation to dose for a series of frequently 









data collection    A literature search was conducted using the following keywords 
in  the  electronic  databases  PubMed,  EMBASE  and  PsychInfo:  ‘antipsychotic’, 
‘occupancy’ and ‘schizophrenia’ (a full description of the search terms can be obtained 
from the author). At  first,  the authors  I.M.L. and K.T. screened  titles and abstracts 
for relevance to  the defined topic and,  if appropriate,  the  full paper was examined. 
References of included articles were checked for other relevant articles. 










was  coded  into  a  binary  variable  indicating  Positron  Emission  Tomography  (PET) 






(SAS),  version  9.2  and  9.3.  Data  were  summarized  using  descriptive  measures 
















































variables  on  the  D2 receptor  occupancy.  The  parameters  in  the  non-linear  mixed 
models were estimated with maximum likelihood using the procedure NLMIXED of 
SAS. More specific details on the statistical analysis are found hereafter. 











were  considered  theoretically  impossible  as  this would  indicate  a negative  binding 
potential  in  a  patient,  and  were  therefore  omitted  from  the  statistical  analysis. 




By  logarithmic  transformation of our data, we were able  to separate  the variability 
between patients and between studies in an additive way, i.e. . 






OD2(x) = θ1 x /(θ2+x), with dose x ≥ 0, θ1ϵ(0 ; 1] the maximal occupancy for the population 
(Emax) and θ2>0,  the dose  that  is associated with 50% reduction  in binding potential 
(EC50).
20,21  In  case  this  dose-response  relationship  includes  a  shape  parameter  q3 
Oij = 
 Zij = ηθ(xij) + ∑ βkukij + γi + εij
Zij = log(1– Oij) = log(BP ij














by  the parameters β0  , β1  , …., βm. The model parameter γi  represents the additive 
random effect of unexplained  inter-study variation  (heterogeneity between studies) 






performance measures    The  total  variation  in  observed  occupancy  values 
was given by the relative standard deviation (RSD).25 The RSD can be expressed as a 
percentage and it is calculated by 100% • √exp{S2 + P2} - 1. Heterogeneity between 

















model building    Model fitting started with the assumption that the dose-response 
relationship for the median occupancy was of the form of Michaelis-Menten (i.e. θ3 








































groups.  Thirdly,  all  three  explanatory  variables  age,  gender  and  imaging  method 
were included in the model, but an intercept was omitted from the model since the 
explanatory variables were centralized with their means. If the reference groups used 




Heterogeneity  between  studies  was  investigated  using  the  likelihood  ratio  test.  If 
heterogeneity was significant at  the  level of α = 0.05, a random effect  for study  (γi) 
was included in the model. The contribution of the three explanatory variables was 
investigated by conducting a backward elimination on the basis of the P-value of these 
variables  for  the Wald statistic. Explanatory variables remained  in  the model  if  the 
largest P-value of the variables was below the significance level of α = 0.05. 
The obtained model was further investigated for goodness-of-fit using the likelihood 
ratio  test.  Firstly,  the  assumption  that  no  bias  was  present  in  baseline  binding 
potential of patients with respect  to  the reference group was verified by evaluating 
















1;  Supplemental  Table  1).  For  86%  complete  information  on  age  and  gender  was 
available, with a mean age of 32.2 (±10.8) years and 25.7% being female (Supplemental 









confounded  the  two  studies.  None  of  the  three  explanatory  variables  significantly 
contributed to the non-linear models at the level of α = 0.05. 
The  95%  confidence  intervals  of  the  estimated  maximum  occupancy  in  Table  1 
suggest that 100% occupancy was not reached by haloperidol, clozapine, quetiapine 
and  aripiprazole.  The  total  relative  standard  deviation  (RSD)  was  high  for  all 
antipsychotics,  especially  for  haloperidol  and  risperidone.  The  high  ICC  value  for 
haloperidol  demonstrated  that  the  variance  in  occupancy  was  predominantly 
explained  by  heterogeneity  between  studies,  whereas  for  risperidone  and  other 




The  goodness-of-fit  investigation  demonstrated  no  significant  bias  in  the  median 
occupancy by baseline binding potential of the reference groups for any antipsychotic; 
the lowest two P-values were obtained for olanzapine (P = 0.051) and quetiapine (P 
=  0.187).  Furthermore,  goodness-of-fit  could  not  demonstrate  a  shape  parameter 
unequal  to  one  for  any  of  the  proposed Michaelis-Menten  curves; with  the  lowest 
p-value  obtained  for  quetiapine  (P  =  0.180).  Agent-specific  hyperbolic  functions 









































Menten function (ÔD2 )(x) = Emax * x/(x + EC50 ) . Total RSD = relative standard deviation; ICC 
= intraclass correlation coefficient, representing heterogeneity between studies a percentage of the 
total  variation; R2 = percentage of  variability  in  the data explained by  the non-linear mixed effects 
model. 
Antipsychotic Emax (θ1 ) EC50 (θ2 ) Total RSD (%) ICC (%) R
2 (%)
Haloperidol 91.9 [86.1 ; 97.8] 0.65 [0.12 ; 1.18] 81.2 [48.2 ; 114] 67.9 [44.9 ; 91.0] 72.4
Risperidone 92.4 [81.8 ; 100] 1.07 [0.30 ; 1.84] 79.7 [62.7 ; 96.8] 26.8 [4.8 ; 48.8] 41.1
Olanzapine 96.5 [85.8 ; 100] 6.46 [2.46 ; 10.5] 52.7 [39.8 ; 65.6] 31.6 [2.5 ; 60.7] 56.7
Clozapine 61.7 [49.2 ; 74.2] 125 [19.8 ; 230] 28.9 [24.3 ; 33.5] 14.2 [0 ; 34.9] 31.1
Quetiapine 49.1 [18.7 ; 79.6] 352 (0 ; 921] 29.4 [23.6 ; 35.1] 0 NA 33.1
Aripiprazole 86.9 [78.2 ; 95.7] 0.25 (0 ; 1.71] 58.8 [33.3 ; 84.2] 0 NA   1.0
Ziprasidone 82.9 [44.9 ; 100] 41.7 (0 ; 119] 42.5 [29.1 ; 55.9] 0 NA   8.9
Amisulpride 85.0 [68.5 ; 100] 137 (0 ; 313] 51.6 [26.6 ; 76.5] 39.7 [0 ; 91.0] 64.3
AD  FIGURE  1  (P.112-115).    Individual  occupancies  and  Michaelis-Menten  curves  describing 
dopamine  D2 receptor  occupancy  for:  A)  haloperidol,  B)  risperidone,  C)  olanzapine,  D)  clozapine, 
E)  quetiapine,  F)  aripiprazole, G)  ziprasidone, H)  amisulpride.    The median D2  receptor  occupancy 
(ÔD2 )  can  be  estimated  by  entering  antipsychotic  dose  (x)  in  the  function 




1a. haloperidol individual and median occupancy












































1c olanzapine individual and median occupancy










1e Quetiapine individual and median occupancy












































1g ziprasidone individual and median occupancy











This  meta-analysis  provided  eight  functions  to  estimate  the  level  of  D2 receptor 
occupancy  for  a  given  antipsychotic  dose  in  patients  with  psychotic  disorders. 
The  dose-occupancy  relationships  of  quetiapine  and  aripiprazole  have  not  been 
modeled by previous meta-analyses. Our dose-occupancy  functions can be used  in 
epidemiological and clinical studies  to compare D2 receptor mediated  (side) effects 
between  antipsychotics  and  doses.  For  example  to  optimize  treatment  strategies 
by  finding  thresholds  of  D2 receptor  occupancy  indicative  for  D2 receptor mediated 






The  dose-occupancy  functions  reflected  the  pharmacodynamic  properties  of 
the  antipsychotics.5  The  maximal  D2 receptor  occupancy  was  high  for  strong 
dopamine  antagonists  (Emax  >  90%;  haloperidol  and  risperidone)  and  could  easily 
be  distinguished  from  low maximal  occupancy  of  weak  dopamine  antagonists  like 
clozapine and quetiapine (Emax < 65%). Strong dopamine antagonists had steep curves 
in  the  therapeutic dose window  in combination with  large  inter-individual  variation 




absolute  values.3  Alternatively,  the  weak  dopamine  antagonists  had  low  maximal 
occupancy  values  and  relatively  little  variability  in  occupancy  values,  suggesting 



















































occupancy  set  at  100%.13  Most  of  the  estimates  of  maximal  occupancy  by  Uchida 
(2011) were within our confidence limits, although their estimates based on plasma 
levels were slightly lower than our estimates based on dose.13 These relatively minor 
differences may  be  related  to  their  selective  inclusion  of  SPECT  studies  providing 
plasma levels and differences in dealing with the data. The comparison with previous 







The  current  meta-analysis  was  the  first  to  quantify  the  differences  in  occupancy 


























low R2  values and wide  confidence bands around  the  lower and upper ends of  the 
curves. We would  therefore  recommend applying  the  functions  of  aripiprazole  and 
ziprasidone  to patients with doses within  the  therapeutic dose range  (aripiprazole: 
1030 mg/day; ziprasidone: 80200 mg/day).43 Patients participating  in  the  imaging 
studies  included  in  this meta-analysis were  relatively  young  (mean age:  32  years), 
so  it  is  unknown  whether  our  findings  can  be  extrapolated  to  elderly  patients. 







can  be  applied  in  epidemiological  and  clinical  studies  investigating  D2 receptor 
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Study Radioligand Antipsychotic Route Patients 
1 Bigliani et al. (2000) 1 [123I] epipride SPET olanzapine oral 5
2 Bressan et al. (2003a) 2 [123I] epipride SPET amisulpride oral 8
3 Bressan et al. (2003b) 3 [123I] epipride SPET risperidone oral 6





spiperone PET haloperidol oral 2
6 Corripio et al. (2005) 6 [123I] IBZM-SPECT ziprazidone oral 10
7 de Haan et al. (2003) 7 [123I] IBZM-SPECT haloperidol oral 11
olanzapine oral 9
8 Dresel et al. (1999) 8 [123I] IBZM-SPECT olanzapine oral 20
9 Farde et al. (1989) 9 [11C] raclopride PET clozapine oral 2
10 Farde and Nordstrom (1992) 10 [11C] raclopride PET clozapine oral 5
haloperidol oral 8
11 Farde et al. (1994) 11 [11C] raclopride PET clozapine oral 16
12 Farde et al. (1997) 12 [11C] raclopride PET clozapine oral 1
haloperidol depot 2
13 Gefvert et al. (2005) 13 [11C] raclopride PET risperidone depot 8
14 Goyer et al. (1996) 14 [11C] raclopride PET clozapine oral 5
haloperidol oral 2
15 Grunder et al. (2006) 15 [18F] fallypride PET clozapine oral 15
16 Grunder et al. (2008) 16 [18F] fallypride PET aripiprazole oral 16
17 Kapur et al. (1996) 17 [11C] raclopride PET haloperidol oral 7
18 Kapur et al. (1997) 18 [11C] raclopride PET haloperidol oral 6
19 Kapur et al. (1999) 19 [11C] raclopride PET clozapine oral 11
olanzapine oral 17
risperidone oral 16
20 Kapur et al. (2000) 20 [11C] raclopride PET quetiapine oral 14
21 Kapur et al. (2001) 21 [11C] raclopride PET clozapine oral 5
22 Kessler et al. (2006) 22 [11C] raclopride PET clozapine oral 6
[18F] fallypride PET quetiapine oral 7
23 Knable et al. (1997) 23 [123I] IBZM-SPECT haloperidol oral 7
risperidone oral 12
24 Kufferle et al. (1996) 24 [123I] IBZM-SPECT risperidone oral 11




Study reference Imaging technique Antipsychotic Route Patients 
quetiapine oral 4
26 Kunstler et al. (2000) 26 [123I] IBZM-SPECT clozapine oral 4
haloperidol depot 12
risperidone oral 7
27 la Fougere et al. (2005) 27 [123I] IBZM-SPECT amisulpride oral 29
28 Lavalaye et al. (1999) 28 [123I] IBZM-SPECT olanzapine oral 22
risperidone oral 13
29 Martinot et al. (1996) 29 [76BR] FLB 457 PET amisulpride oral 11
30 Meisenzahl et al. (2000) 30 [123I] IBZM-SPECT olanzapine oral 20
31 Nikisch et al. (2010) 31 [18F] fallypride PET quetiapine oral 5
32 Nordstrom et al. (1993) 32 [11C] raclopride PET clozapine oral 2
33 Nordstrom et al. (1995) 33 [
11C] N-methyl-
spiperone PET haloperidol oral 6
34 Nordstrom et al. (1998) 34 [11C] raclopride PET olanzapine oral 3
35 Pickar et al. (1996) 35 [123I] IBZM-SPECT clozapine oral 7
36 Raedler et al. (1999) 36 [123I] IBZM-SPECT olanzapine oral 10
37 Regenthal et al. (2005) 37 [123I] IBZM-SPECT risperidone oral 8
38 Remington et al. (2006) 38 [11C] raclopride PET risperidone depot 9
39 Schmitt et al. (2002) 39 [123I] IBZM-SPECT risperidone oral 20
40 Stephenson et al. (2000) 40 [123I] epipride SPET quetiapine oral 6
41 Talvik et al. (2001) 41 [11C] raclopride PET clozapine oral 4
haloperidol oral 3
42 Tauscher et al. (1997) 42 [123I] IBZM-SPECT haloperidol oral 1
quetiapine oral 1
43 Tauscher et al. (1999) 43 [123I] IBZM-SPECT clozapine oral 6
haloperidol oral 10
olanzapine oral 6
44 Uchida et al. (2008) 44 [11C] raclopride PET risperidone depot 7
45 Uchida et al. (2009) 45 [11C] raclopride PET risperidone oral 4
46 Vernaleken et al. (2004) 46 [18F] fallypride PET amisulpride oral 9
47 Vernaleken et al. (2008) 47 [18F] fallypride PET ziprazidone oral 15
48 Vernaleken et al. (2010) 48 [18F] fallypride PET quetiapine oral 16
49 Vesely et al. (2000) 49 [123I] IBZM-SPECT quetiapine oral 2
50 Wiesel et al. (1990) 50 [11C] raclopride PET haloperidol oral 1













































Studies (N) Patients (N) Age  Gender  Dose  Occupancy 







Haloperidol 10 6 41 49 29.9 40.7 6.78 75.7
Risperidone 7 8 47 84 33.8 28.3 4.40 67.9
Olanzapine 4 8 24 97 30.9 30.9 13.8 61.5
Clozapine 13 5 75 31 33.8 31.7 384 43.0
Quetiapine 4 4 42 13 34.4 20.0 542 25.0
Aripiprazole 1 - 16 0 30.3 0.0 18.8 83.0
Ziprasidone 1 1 15 10 30.5 26.7 126 58.0
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Optimizing  limbic  selective D2/D3  receptor 
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8.0|  ABSTRACT 
background    Altered  emotional  experiences  in  response  to  antipsychotics 
may  increase  the burden of disease  in patients with schizophrenia. We studied  the 
association  between  altered  emotional  experiences  and  D2  receptor  affinity  and 
occupancy for six frequently prescribed antipsychotics.
methods    In  a  cross-sectional  study,  patients with  schizophrenia  completed  the 
Subjects Reaction to Antipsychotics questionnaire to assess whether they attributed 
altered  emotional  experiences,  operationalized  as  flattened  affect  or  depressive 





regression  analysis  we  also  compared  the  risk  of  altered  emotional  experiences 
between patients using antipsychotic monotherapy and combination therapy. 





more  likely  to  attribute depressive  symptoms  to  their  antipsychotics  than patients 
using antipsychotic monotherapy (OR[95%CI] = 1.443[1.033  2.015]). 

























































Patients  with  schizophrenia  may  experience  altered  emotions  in  response  to 
antipsychotic  treatment,1-3  also known as neuroleptic  dysphoria. Altered emotional 
experiences  include  depressive  symptoms,  flattened  emotions  or  inability  to 
experience pleasure  (anhedonia).  They  further  increase  the  burden of  disease  and 
lead to non-adherence with antipsychotic medication.4,5
Antipsychotics exert at  least part of  their  therapeutic effect by blockade of  striatal 
dopamine receptors.6 Animal research has shown that chronic blockade of dopamine 
D2 receptors  in  the mesolimbic  brain  areas  disturb  the  reward  system, which may 
lead  to relative anhedonia.7,8 A dose-dependent relationship with altered emotional 
experiences has been demonstrated for first generation antipsychotics in patients with 








antipsychotics  with  medium  or  weak  affinity  for  the  D2  receptor.
12,14,15  It  remains 
unknown whether antipsychotics with   weak affinity  for  (or rapid dissociation from) 







in  a  large  cross-sectional  sample  of  patients  with  psychotic  disorders  using  six 








with  schizophrenia  or  related  psychotic  disorders  receiving mental  health  care  in 
the  North  of  the  Netherlands,  who  participated  in  the  annual  screening  program 
Pharmacotherapy Monitoring and Outcome Study  (PHAMOUS).19,20 The  investigation 
was carried out between January 2007 and April 2010 and was  in accordance with 




Patients  having  difficulties  filling  out  the  questionnaires  due  to  concentration 
problems or cognitive impairment received help from the nurse during the screening. 




conducted  the  Positive  and  Negative  Symptom  Scale  for  Remission  (PANSS-R) 
interview  to  assess  whether  the  patients’  psychotic  symptoms  were  in  remission, 
which  is rated on  the same 7-point Likert scale as  the  full version of  the PANSS.25 
Medication use over the past year was retrieved from medical records and confirmed 
with the patient.




rating of emotional experiences    The SRA has 74 items and showed a good 
test-retest reliability and validity in patients with schizophrenia.21 The SRA was rated 
on a three-point scale (no / yes, mild / yes, severe). Factor analysis of the SRA has 



































































antipsychotic d2 receptor affinity and occupancy    Patients  using 
antipsychotic mono-therapy were grouped according to four levels of affinity [Ki] for 
the dopamine D2 receptor of their antipsychotic: high for haloperidol and risperidone 
(Ki<1nM),  medium  for  olanzapine  (1<Ki<10nM),  weak  for  clozapine  and  quetiapine 
(Ki>10nM).




The  level  of  D2  receptor  occupancy  of  each  individual  subject  was  estimated  by 
applying dose-occupancy equivalents to the daily dose as described by Lako (2012).29 
The  doses  of  antipsychotic  depot  preparations  were  first  converted  into  oral  daily 











pipamperone  or  sertindole.  For  each  patient,  we  selected  the  highest  level  of 







variables  were  not  normally  distributed  and  were  therefore  assessed  by  the  non-
parametric  Mann-Whitney  U  test.  Correlations  were  calculated  using  Spearmans’ 
correlations.  The  association  of  altered  emotional  experiences  with  the  level  of 
antipsychotic  D2  receptor  affinity  and  the  estimated  level  of  dopamine  D2 receptor 
occupancy  was  quantified  using  logistic  regression  analysis.  Dependent  variables 
were “flattened affect” and “depressive symptoms”. The levels of affinity, occupancy 
as  well  as  the  individual  six  antipsychotics  were  entered  as  categorical  variables. 






antipsychotics  were  compared  by  entering  the  six  antipsychotics  as  categorical 
independent variable with haloperidol as reference category in an additional model. 
In  a  separate  analysis  we  compared  the  effect  of  antipsychotic monotherapy  with 
combination  therapy on both altered emotional experiences. The goodness of  fit of 

























































subjects      Out of n=2241 patients with psychotic disorders, n=142  (6%) patients 
were antipsychotic  free, n=200  (9%) did not use one of  the selected antipsychotics, 
n=36 (2%) had incomplete information on antipsychotic dose and n=565 (25%) of the 
patients  did  not  complete  (the  selected  items  of)  the  SRA  questionnaire.  In  total, 
n=1298 patients were included in the study (Table 1), of whom=302 (23%) perceived 
flattened affect and n=212 (16%) depressive symptoms in response to antipsychotic 
treatment.  Of  note,  n=103  (8%)  of  all  included  patients  reported  both  experiences 
in  response  to  antipsychotics.  Male  patients  perceived  flattened  affect,  but  not 
depressive  symptomatology,  more  frequently  in  response  to  antipsychotics  than 







antipsychotic monotherapy    Antipsychotic  monotherapy  was  used  by 
n=1010  (78%)  patients  (Table  2).  Depot  formulations  were  used  by  (n=34;  40%) 
of  the  haloperidol  users  and  (n=92;  31%)  of  the  risperidone  users.  The  level  of 
D2  receptor  occupancy  among  patients  with  antipsychotic  mono-therapy  was 
distributed  over  the  following  three  intervals:  [0.1  -  48.3%];  [48.3    71.1%];  [71.1 
  89.0%].  Logistic  regression  showed  no  relationship  between  antipsychotic 
D2 receptor affinity and altered emotional experiences in patients using antipsychotic 
mono-therapy. There was neither a relationship when corrected for binding affinity, 
nor  an  interaction  effect  between  binding  affinity  and  D2  receptor  occupancy  and 
altered emotional experiences.  In a comparison of all six  individual antipsychotics, 
patients  treated  with  quetiapine  appeared  to  be  less  likely  to  report  depressive 




antipsychotic combination therapy    Antipsychotic  combination  therapy 





estimated  D2 receptor  occupancy  was  determined  for  n=275  (95%)  of  the  patients 
using  combination  therapy.  The  remainder  used  medication  for  which  no  dose-
occupancy equivalents were available. The mean D2 receptor occupancy for patients 
on combinations (74%; SD11.5) was higher than for patients on mono-therapy (58.0%; 
SD19.8;  p<0.001),  see  Table  2.  In  addition,  patients  using  combination  therapy  had 
higher mean PDD/DDD ratios than patients using antipsychotic monotherapy (p<0.001). 
Patients  using  antipsychotic  combination  therapy  were  more  likely  to  attribute 



























































We  investigated  the  relationship  between  altered  emotional  experiences  and 
antipsychotic D2  receptor affinity and occupancy  in a  large sample of patients with 
psychotic disorders. The antipsychotics that were used in the sample represented a 
wide range of D2 receptor affinities, including quetiapine, clozapine and aripiprazole. 
The  main  finding  was  that  patients  using  antipsychotics  with  weak  affinity  for 
the  D2 receptor  were  as  likely  to  attribute  altered  emotional  experiences  to  their 
antipsychotics  as  patients  using  antipsychotics  with  higher  D2  receptor  affinities. 
Although  a  trend  of  a  reduced  risk  to  induce  depressive  symptoms was  observed 
for quetiapine compared to haloperidol, potential differences between antipsychotic 
monotherapy  treatments  in  altered  emotional  experiences  may  be  marginal 




of  these  antipsychotics.14  In  our  sample,  patients  using  antipsychotics  with  high 
affinity for the D2 receptor received recommended doses of about 4 mg haloperidol 





The  increased  likelihood  of  patients  using  antipsychotic  combination  therapy 
attributing  depressive  symptoms  to  antipsychotics  compared  to  patients  using 
monotherapy suggested involvement of D2 receptor occupancy. The cumulative daily 
dose of most patients using antipsychotic combination therapy was high and exceeded, 




as  effect  moderator  in  the  relationship  with  these  altered  emotional  experiences 
was however difficult  in patients using antipsychotic combination  therapy, because 






for  the  serotonin  5-HT2A  receptor  reduces  altered  emotional  responses  by  having 
antidepressant  effects.37-39,40  First  generation  antipsychotics  lacking  affinity  for  this 
receptor would be more  likely  to have depressogenic effects.41 Others suggest  that 
the  serotonergic  modulation  of  the  dopamine  system  cannot  compensate  for  the 
dopamine  receptor  blockade  by  second  generation  antipsychotics.18  The  serotonin 
hypothesis is under debate, since recent studies failed to detect a differential effect 
between antipsychotics in the treatment of depressive symptomatology.42-44 Likewise, 






interview assessment.38,46  Self-report may be preferred  for  the  rating  of  emotional 
experiences, since some parts of the patients’ affective state are difficult to measure 
by observational ratings and the patients’ attribution of treatment effects has found 






To  conclude,  our  study  showed  that  a  considerable  number  of  patients  with 
schizophrenia  attributed  altered  emotional  experiences  to  their  antipsychotic 
medication. We could not confirm an association between these experiences and the 
level of D2 receptor affinity or occupancy in patients with antipsychotic monotherapy, 
possibly because  the dosing strategies were adequate. The  increased  likelihood of 
patients  using  antipsychotic  combination  therapy  attributing  depressive  symptoms 
to  their  antipsychotics,  however,  suggested  a  dose-relationship  with  D2  receptor 
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summary background of the thesis
Patients with schizophrenia have a high burden of disease. Many of  them suffer  from 











unclear  whether  depressive  symptoms  in  response  to  antipsychotics  represent  a 
separate symptom dimension from other (affective) side effects. Furthermore, there is 
a  lack  of  dose-occupancy  equivalents  describing  antipsychotics with weak affinity  for 
the D2  receptor. Finally,  the  relation between depressive  symptoms and antipsychotic 
D2 receptor  affinity  and  occupancy  needs  additional  investigation  for  a  wide  range  of 
antipsychotics,  including  antipsychotics  with  weak  affinity  for  the  D2 receptor.  More 
understanding  of  (secondary)  depressive  symptoms  aids  the  clinician  in  finding  an 
optimal treatment strategy for depressive symptoms. 
This  thesis  investigated  the  recognition  of  depressive  symptoms  in  patients  with 
schizophrenia by: 
  •  Describing  the course of depressive symptoms  in  relation  to  the prescription 
patterns  of  antidepressants.  Comparing  the  psychometric  properties  of 
depression  instruments  that  can  be  used  for  the  monitoring  of  depressive 
symptoms  in  clinical  practice  of  patients  with  schizophrenia.  Exploring  the 




of  a method  to measure  depressive  symptoms  in  response  to  antipsychotics 














course of depressive symptoms over time 















Of  the  patients  having  depressive  symptoms  at  baseline,  the majority  kept  having 
depressive  symptoms  despite  continuing  antidepressant  therapy.  Moreover,  we 
identified  the  use  of  co-medication  as  a  predictor  for  patients  to  keep  having 
depressive  symptoms,  instead  of  remitting  from  depressive  symptoms.  Although 
this  observational  study  could  not  evaluate  the  effectiveness  of  antidepressants  in 
patients with schizophrenia, we know from two recent systematic literature reviews 
that the effectiveness of antidepressants is unclear in this population.8,9 We therefore 
recommend  close monitoring  of  the  treatment  of  patients  with  schizophrenia  and 
depressive symptoms, particularly in those patients using co-medication. 
recognition of depressive symptoms in schizophrenia
overview of depression instruments    The  review  in  Chapter  3  aimed 








in populations with schizophrenia. Three other  instruments  included  for evaluation 
were  primarily  developed  for  use  in  depressed  populations  and  another  two were 
depression  subscales  of  psychotic  symptom  rating  scales.  We  demonstrated  that 
the CDSS interview outperformed other depression scales on discriminative validity 
for  the negative symptom dimension and other aspects of  reliability and validity  in 
patients with schizophrenia. The other depression  instruments were more  likely  to 
misdiagnose negative symptoms as depressive symptoms than the CDSS. This was 
illustrated by analysis of  the content of  the depression  instruments. All depression 
scales,  except  for  the  CDSS,  contained  one  or  more  items  tapping  into  negative 
symptoms of schizophrenia (Figure 1). 
Another outcome of the study was the gap in literature regarding validated self-report 
depression  instruments  in  this  population.  No  self-report  depression  instrument 
was especially designed for use in patients with schizophrenia. The only self-report 
instrument  that was  tested  on  a  full  set  of  psychometric  properties was  the Beck 
Depression Inventory (BDI), but its predictive validity to detect cases of depression was 
poor in patients with schizophrenia. We aimed to find a valid self-reported depression 




Studies-Depression  (CES-D)11  in  patients  with  schizophrenia  were  limited,  but 
promising.12-14 Evaluation of the composition of these instruments demonstrated that 
especially  for  the  CES-D  a minimal  number  of  items  tap  into  negative  symptoms, 
compared  to  other  self-report  depression  instruments  (Figure  1).  The  concurrent 
validity of the QIDSSR16 and the CES-D self-report scales was compared with the CDSS 
as  the  golden  standard  depression  rating  scale  for  patients  with  schizophrenia  in 
Chapters 4 & 5. 
The percentage of items covering the core depressive symptoms was compared with 





























self-report measures of depressive symptoms in patients with 
schizophrenia    The results described in Chapter 4 suggest that not all depres-
sion  instruments  are  suitable  for  use  in  patients with  schizophrenia.  Although  the 







































































CDSS as golden standard depression rating scale  (r=0.44)  in a  large sample of pa-
tients with schizophrenia or related psychotic disorders. This moderate correlation 
suggests differences with the CDSS. 
The  scores  on  the  QIDS-SR16  dimensions  measuring  the  physical  symptoms  of 
depression were relatively high and discordant with the CDSS in this population. This 
was in most cases driven by the items ‘excessive sleep’ and ‘increased appetite’, which 
may  reflect  side effects  of  antipsychotics,15,16  and hence not necessarily  be  related 







to  confounding  by  antipsychotic  side  effects.  Thus,  not  only  the  measurement  of 
extrapyramidal side effects, but also sedative effects from antipsychotics should be 
avoided  in  the assessment of depressive symptoms  in patients with schizophrenia. 
Another  symptom  that  is  well  covered  by  CDSS  and  the  CES-D,  but  not  the 
QIDS-SR16 is hopelessness. Patients with schizophrenia may be prone to psychological 
depressive  symptoms  like  hopelessness  and  self-depreciation,  possibly  related  to 
demoralization  in  response  to  the severe mental  illness.18  In conclusion, we would 
not recommend to measure depressive symptoms by the QIDS-SR16 in patients with 
schizophrenia or psychotic disorders. 
Chapter  5  showed  that  the  CES-D  is  a  promising  self-report  for  the  monitoring 
of  depressive  symptoms  in  patients  with  psychotic  disorders.  In  contrast  to  the 





















The  good  internal  consistency  of  the  CES-D  in  patients  with  psychotic  disorders 
suggests  that  the patients are able  to rate  their depressive symptoms  in a reliable 
way.19 We noticed that the patients experienced minimal effort to complete the CES-D 
questionnaire.  Instead, previous studies reported that at  least 10% of patients with 
schizophrenia  had  difficulties  to  complete  the  BDI  questionnaire.20,21  The  answer 
categories of the BDI consist of four statements, which differ for each question, thus 
all these statements need to be read separately. Patients may find it easier to complete 
a  uniform  Likert  scale  with  a  visual  degree  of  severity  like  the  CES-D,  especially 
those  patients  with  concentration  problems  associated  with  schizophrenia.21  The 
current results suggest  that  the CES-D  is a  feasible self-report  instrument  for  the 
measurement of depressive symptoms in patients with schizophrenia. As a limitation 
of this study, we were not able to determine the discriminative validity of the CES-D 
to  distinguish  depressive  symptoms  from  negative  symptoms  or  extrapyramidal 
symptoms. Future research will be needed to address this issue.
One of the lessons we learned, is that there is a lot of variation in the reliability and 
validity  of  depression  instruments  in  patients  with  schizophrenia.  In  view  of  the 
upcoming  DSM-V, monitoring  the  severity  of  symptom  dimensions  over  time may 
become more important than predicting dichotomous outcomes. This thesis therefore 
focused on  instruments  to monitor  (sub-syndromal)  depressive  symptoms and not 
on  diagnostic  classifications  predictive  for  a  major  depressive  episode.  Still,  we 
feel obliged  to address some  inconsistencies  in  the prevalence rates of depressive 






























diagnoses  were  not  systematically  recorded  in  both  studies,  we  were  not  able  to 
determine a cut-off score of the QIDS-SR16 with an optimal sensitivity and specificity 
to detect cases of depression in this population. Future research may be needed to 
find a more optimal cut-off  score  for  the CES-D,  to optimize  the predictive  validity 




Depression instrument Cut-off score Sample Prevalence 
Clinician rating ≥ 2 out of 3 ROM (2006), Chapter 2 43%
CDSS (observer rated) ≥ 5 out of 27 GROUP (2011), Chapter 4 17%
QIDS-SR (self-report) ≥ 6 out of 27 GROUP (2011), Chapter 4 52%
CDSS (observer rated) ≥ 5 out of 27 PHAMOUS (2011), Chapter 5  10%
CES-D (self-report) ≥ 15 out of 60 PHAMOUS (2011), Chapter 5  38%
conceptual issues of depression in patients with schizophrenia    The 















only  five of  the nine DSM-IV criteria  for depression are partially useful  to detect 
depressive  symptoms  in  patients  with  schizophrenia.  Consequently,  the  item 
composition of a depression instrument especially designed to measure depressive 






currently  considered  less  relevant.24  Although  concepts  and  views  have  changed, 
the CDSS covers  these depressive symptoms  in an acceptable way. The CDSS well 
avoids  the  measurement  of  negative  symptoms  and  the  effects  of  antipsychotics 





symptoms.  Future  research  is  needed  to  evaluate  a more  optimal  cut-off  score  in 
patients with schizophrenia. Ideally a new self-report scale may need to be developed 
to assess depressive symptoms in this population. 
suggestions for a new self-report depression instrument    The 
symptom dimensions that should be covered by a self-report depression instrument, 
especially designed for use  in a population with psychotic disorders, are discussed 
here.  In  our  opinion  such  a  self-report  depression  instrument  should  address  the 
following symptoms: 1) depressed mood or feeling sad, 2) hopelessness, 3) suicidal 
ideation  4)  worthlessness  but  not  guilt.  Since  the  patient  may  have  difficulties  to 
disentangle  delusional  feelings  of  guilt  from  ruminating  over  minor  past  failures 
as part of depression, it was felt to be inappropriate to measure guilt by self-rating. 
Changes  in  5)  sleep  and  6)  appetite  can  be  included,  as  long  as  they  measure  a 









to  actual  or  potential  positive  events)  or  diurnal  variation  (morning  depression). 
If  needed,  the  instrument  can  be  expanded  with  symptoms  commonly  associated 
with  depression,  including  cognitive  symptoms  (e.g.  pessimism  about  the  future 
or  feelings  of  loneliness)  and  psychological  symptoms  (e.g.  crying  spells  or  an 
exaggerated sense of frustration about minor matters). Examples of statements that 
tap  into  these symptoms can be found  in  the CDSS, CES-D, Symptom Checklist-90 
depression  subscale  (SCL-90-D)  and  Zung  Self-rating  Depression  Scale  (Zung-





depressive symptoms attributed to antipsychotics
subjects’ response to antipsychotics-34    The main outcome of the study 
in Chapter 6  is  that we developed the SRA-34 as quick  tool  to measure depressive 
symptoms,  amongst  other  experiences,  in  response  to  antipsychotics.  The  SRA-
34 addresses a wide range of both desired and undesired effects that patients may 
experience  in  response  to  their  antipsychotics.  Although we wished  to  reduce  the 
number of items of the SRA-74 as much as possible, the clinical reality of heterogeneous 
side  effects  did  not  allow  us  to  further  reduce  the  SRA-34  while  maintaining  a 


























antipsychotics,  independent  of  other  drug-induced  emotional  experiences  or  EPS. 
The  identification  of  the  depressive  dimension  in  response  to  antipsychotics  was 
novel, while most  other  symptom dimensions  identified  by  factor  analysis were  in 
line with the original subscale structure of the SRA-74.32 Our large sample enabled 








methodological challenges in the development of Questionnaires
In the development of the SRA-34 questionnaire to assess experiences in response 
to  antipsychotics,  we  choose  to  perform  exploratory  factor  analysis  (EFA)  on 





















mechanism  in  patients with  schizophrenia.  Likewise,  similarity  analysis  confirmed 
that  inability  to  sit  still  (akathisia)  was  not  associated  with  other  extrapyramidal 
side effects. We would therefore recommend supporting exploratory factor analysis 
of  a multidimensional  questionnaire  by  visualization  of  the  latent  structure,  using 
similarity analysis based on mutual information. 
dopamine involvement in depressive symptoms attributed 
to antipsychotics 
antipsychotic dose and dopamine d2 receptor occupancy    In order 












Our meta-analysis  improved  the  knowledge  on  the  variability  in  occupancy  values. 
We were the first to separate inter-individual variability from inter-study variation in 
D2 receptor occupancy, using a non-linear mixed model. We observed high variability 





by  inter-individual  variability.  The  high  inter-individual  variability  in  D2  receptor 
occupancy implied that our antipsychotic dose equivalents, as well as the conventional 













imprecise  when  applied  to  individual  cases.  These  inter-individual  differences 
are most  likely  related  to  differences  in metabolism  or  genetic  background.43  The 
high  inter-individual  variability  further  underlines  the  need  for  individual  dosing 
strategies to avoid side effects in response to excessive D2 receptor occupancy. Our 
dose-occupancy equivalents are optimal to study D2 receptor mediated antipsychotic 
effects in a population,  in case  in vivo occupancy measures of the patients are not 




methodological challenges in meta-analysis of published occupancy 




assumed  that  infinite  doses  of  antipsychotics  could  occupy maximal  level  of  100% 
of the dopamine D2 receptors by fixing the horizontal asymptote to 100%,
33 although 




improved  those  unconstrained models  by  assuming  that  also  the  95%  confidence 
interval around the estimated maximal level of D2 receptor occupancy should remain 


















may  theoretically  occupy  100%  of  the  D2 receptors,  the  effect  of  combining 
antipsychotics  on D2  receptor  occupancy may  not  simply  be  additive.  Alternatively, 
the cumulative dopaminergic  load of a patient  could be expressed by a  risk score, 
analogous to the formula that describes the anticholinergic load of medications.49 The 
development of measures of  the dopaminergic  load  in patients using antipsychotic 
combination therapy can be useful for further investigation of a possible relation with 
antipsychotic-induced depressive symptoms. 
dopamine involvement in depressive symptoms attributed to 
antipsychotics      In  contrast  to  previous  hypotheses,50,51  Chapter  7  suggests 
that  antipsychotic-induced  depressive  symptoms  are  not  related  to  antipsychotic 
D2  receptor  affinity  or  occupancy  in  patients  using  antipsychotic monotherapy. We 










monotherapy  may  have  withheld  us  from  identifying  D2 receptor  occupancy  as  an 
effect modifier/moderator in patients using antipsychotic monotherapy.
The  increased  likelihood  of  patients  using  antipsychotic  combination  therapy 
attributing  depressive  symptoms  to  their  antipsychotics,  however,  suggested  a 
relationship with excessive D2 receptor occupancy. One out of four patients received 
antipsychotic combination therapy and most of them received high cumulative doses 
and  correspondingly  high  estimated  levels  of  D2  receptor  occupancy.  However,  we 















occupancy.  Altogether, we would  recommend  being  cautious with  the  prescription 
of  combination  therapy,  especially  in  high  doses,  to  avoid  undesired  emotional 
experiences in response to excessive D2 receptor blockade. 
implications for clinical practice 
recognition of depressive symptoms in patients with schizo- 
phrenia    We would  recommend  the Calgary Depression Scale  for Schizophrenia 
(CDSS) interview for the screening and monitoring of depressive symptoms in clinical 
practice and research (Chapter 3). The training of research nurses in the CDSS takes 
about half a day. Educating staff  in  the use of  the CDSS contributes  to  the general 
knowledge of specialists  in psychotic disorders about depression.  In daily practice, 
nurses offer psychosocial interventions and education helps them to recognize which 
symptoms  are  important  to  recognize  in  an  early  stage  of  depression.53  Also,  the 





in care  is considered  feasible, except  in a  few cases where  individuals have severe 















recognition of (emotional) experiences in response to anti-
psychotics    For routine monitoring of experiences in response to antipsychotics, 
including depressive symptoms, we advise to use SRA-34 as a quick and comprehensive 




and expert opinion of other  instruments.28,29 When using  the SRA-34,  in addition  to 




routine outcome monitoring    The recognition of depressive symptoms can 
be  further  improved by adopting depression  instruments as part of  annual  routine 
monitoring  (ROM).  ROM may  guide  this  diagnostic  process  by  providing  additional 
information  about  possible  relapse  psychosis,  differential  diagnoses,  and multiple 
symptom dimensions at the same time. An example of comprehensive annual ROM 
is  the  Pharmacotherapy  Monitoring  and  Outcome  Survey  (PHAMOUS),  designed 
to  monitor  the  mental  and  physical  health  of  patients  with  psychotic  disorders. 
PHAMOUS  is  implemented  in  all  mental  health  care  organizations  in  the  North 
of  the Netherlands and provided  the data  for Chapters 2, 4, 6 and 8. The rationale 
for  this  screening  is  that  patients  with  schizophrenia  were  considered  to  have  an 
increased mortality risk, possibly related to their unhealthy lifestyle56,57 and genetic 



















improvement of treatment guidelines for depressive symptoms 









predict  the  prognosis  of  psychopathology  and  identify  persons  at  risk  of  a  poor 
outcome.63  Integrating  measures  of  symptom  severity  with  risk  factors,  such  as 
psychopathology and co-medication (see Chapter 2) in the management of depressive 
symptoms, may improve individualized care. 
Guidelines  provide  no  specific  recommendations  for  the  treatment  or  prevention 
of  depressive  symptoms  attributed  to  antipsychotics,  besides  a  preference  for 
second  generation  antipsychotics.6,52,62  Since  our  findings  suggested  a  relationship 
with depressive symptoms  in patients using antipsychotic combination  therapy, we 
would recommend being cautious with the prescription of antipsychotic combination 
therapy,  especially  in  high  doses.  Furthermore,  since  we  identified  co-medication 
(benzodiazepines,  antidepressants)  as  risk  factor  to  have  persisting  depressive 
symptoms, we would advocate minimizing the total number of drugs in this population. 
More extensive research is needed to evaluate effects of lowering the number of drugs 
or antipsychotic doses on depressive symptoms,  in order  to  improve the  treatment 
guidelines for patients with schizophrenia. 











patients  attribute  to  their  antipsychotics.  In  case  depressive  symptoms  would  be 
related to (self)stigma, the clinician may help these patients to cope with their disease 
by psycho-education or cognitive behavioral therapy (CBT). 
A  considerable  number  of  patients  with  subsyndromal  depressive  symptoms may 
suffer from demoralization syndrome,18 it may be difficult to disentangle demoralization 
syndrome  from  depression.  Patients  with  demoralization  syndrome  benefit  more 
from  psychosocial  approaches  rather  than  pharmacotherapy  by  antidepressants. 
Psychosocial  treatment  options  include  cognitive  behavioral  therapy  (CBT)  to  help 
patients  to mourn  their  losses  and  cope  with  the  disease,66,67,68  or  other  forms  of 
psychosocial  treatment  that  help  patients  to  address  feelings  of  low  self-esteem 
and hopelessness, set realistic goals, and develop skills to attain them.69 Improving 
the  recognition of demoralization syndrome could contribute  to a better choice  for 
effective treatment. 
some concluding remarks    Depressive  symptoms are  prevalent  in  patients 
with schizophrenia. Antidepressants are frequently prescribed and maintained in the 
treatment of depressive symptoms. In clinical practice, clinicians may have difficulties 
to  adequately  distinguish  depressive  symptoms  from  negative  symptoms  and  side 




other  altered  emotional  experiences.  Antipsychotic  combination  therapy  has  been 
associated  with  depressive  symptoms,  suggesting  a  relationship  with  excessive 
dopaminergic  blockade.  A  dose-response  relationship  with  D2  receptor  occupancy 
could however not be confirmed in patients using antipsychotic monotherapy, probably 
because of cautious dosing strategies. Still,  the high  inter-individual differences  in 
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of  this  thesis  is  to  describe  the  relationship  between  depressive  symptoms  and 
D2 receptor affinity and occupancy.
summary of chapter 2-8    Antidepressants  are  frequently  prescribed  in 
patients with psychotic disorders, although their effectiveness is unclear in patients 
with  schizophrenia.  Chapter  2  describes  the  course  of  depressive  symptoms  in 
relation  with  prescribing  patterns  of  antidepressants  and  identifies  predictors  for 
having  persistent  depressive  symptoms.  Depressive  symptoms  of  a  cohort  of  214 
patients with  schizophrenia were  rated  by  their  clinician  as  part  of  annual  routine 





polypharmacy  was  a  potential  risk  factor  to  keep  having  depressive  symptoms. 
Patients with more severe psychopathology had a higher risk to develop depressive 
symptoms the following year. 
Chapter  3  is  a  systematic  review  of  the  literature  on  depression  instruments with 
published measures of  reliability and validity  in patients with schizophrenia. Forty-
eight  publications  described  the  performance  of  six  depression  instruments  in 
patients  with  schizophrenia,  including  three  depression  instruments  primarily 
developed for use in depressed populations and two depression subscales of psychotic 
symptom scales.  The  only  depression  instrument  especially  developed  for  the  use 
in patients with schizophrenia was the Calgary Depression Scale  for Schizophrenia 
(CDSS) interview. The CDSS outperformed other depression scales in this population, 
since  it  correlated  well  with  other  depression  instruments  (concurrent  validity), 
169
most  accurately  differentiated  depressive  symptoms  from  negative  symptoms  of 
schizophrenia  (divergent  validity)  and was  least  likely  to miss  cases  of  depression 
or misdiagnose depression  (predictive  validity). We would  recommend utilizing  the 
CDSS interview for the measurement of depressive symptoms in research and in daily 
clinical practice of patients with schizophrenia. 








report  depression  instrument. Because  its  validity  has  not  extensively  been  tested 
in  patients  with  schizophrenia,  Chapter  4  evaluated  several  aspects  of  reliability 
and  validity of  the QIDS-SR16  in 621 patients. Our study showed  that patients were 
able to reliably rate their depressive symptoms using the QIDS-SR16. The QIDS-SR16 
well discriminated depressive symptoms  from negative symptoms, as  rated by  the 

















that  overlap  with  negative  symptoms,  compared  to  other  self-report  depression 
instruments.  Future  research  is  needed  to  determine  the  predictive  validity  of  the 
CES-D to detect cases of depression in patients with schizophrenia. 
Depressive  symptoms  can  be  one  of  the  side  effects  of  antipsychotics.  Chapter 
6  investigated  if  patients  attribute  depressive  symptoms  to  their  antipsychotics, 
independent from other antipsychotic side effects. The main aim of this chapter was 
to  develop  a  shorter  version  of  the  74-item  Subjects’  Response  to  Antipsychotics 




expert  panel. Exploratory  factor  analysis  of  the SRA-74  identified  fourteen  factors, 
including one  factor of depressive symptoms. This  implied  that  the  two depression 
items ‘I feel down’ and ‘I feel more depressed’ of the SRA-74 can be used to investigate 
the  patients’  attribution  of  depressive  symptoms  to  antipsychotics.  The  number  of 
























type  (affinity)  or  dose  (occupancy).  We  investigated  the  effect  of  monotherapy 
and  combinationtherapy  on  depressive  symptoms  in  patients  with  schizophrenia, 





as  an  antipsychotic  side  effect.  Logistic  regression  analysis  could  not  confirm  an 
association between depressive symptoms and antipsychotic D2 receptor affinity or 
the level of D2 occupancy in patients using antipsychotic monotherapy. Patients using 
antipsychotic  combination  therapy  (22%)  were  more  likely  to  attribute  depressive 
symptoms  to  their  antipsychotics  than  patients  using  antipsychotic  monotherapy 
(OR[95%CI] = 1.443[1.033  2.015]). The high cumulative doses prescribed for patients 
using  antipsychotic  combination  therapy  suggested  a  dose-response  relationship 
between  depressive  symptoms  and  D2  receptor  occupancy.  We  would  recommend 
being  cautious  with  prescribing  antipsychotic  combination  therapy  to  avoid  drug-
induced depressive symptoms. 




symptoms  from other psychotic  symptoms  in  this population. The use of  validated 
instruments  like  the  Calgary  Depression  Scale  for  Schizophrenia  (CDSS)  aids  the 
clinician in the recognition of depressive symptoms, and may thereby prevent over-










dopaminergic  blockade.  A  dose-response  relationship  with  D2  receptor  occupancy 
can however not be confirmed in patients using antipsychotic monotherapy, probably 
because of cautious dosing strategies. Still,  the high  inter-individual differences  in 
occupancy  values  for  a  given  antipsychotic  dose  underline  the  need  for  individual 
dosing strategies. Shared decision making between patient and clinician is an elegant 






belemmerd  kan  worden  in  sociaal  en  maatschappelijk  functioneren.  Mensen  met 
schizofrenie  hebben  last  van  waanideeën,  of  horen  stemmen  die  er  niet  zijn.  In 




te  achterhalen,  wat  een  effectieve  behandeling  in  de  weg  kan  staan.  Depressieve 
symptomen  lijken  namelijk  op  andere  symptomen  die  met  schizofrenie  gepaard 
gaan,  zoals  een  afgevlakt  gevoelsleven  en  sociale  teruggetrokkenheid  (negatieve 
symptomen). Ook is het niet uitgesloten dat depressieve symptomen een bijwerking 
zijn  van  de  antipsychotica,  waarmee  de  patiënten  doorgaans  worden  behandeld. 
Daarnaast kan deze neerslachtigheid te maken hebben met een drastisch veranderd 
toekomstperspectief,  ten  gevolge  van  deze  psychiatrische  aandoening.  Afhankelijk 
van de aard van de depressieve klachten, kunnen deze patiënten behandeld worden 
met  antidepressiva,  een  aanpassing  in  de  behandeling  met  antipsychotica,  of 
gesprekstherapie. 
samenvatting hoofdstuk 2-8    Het  is  bekend  dat  antidepressiva  veelvuldig 










van  depressieve  symptomen  was.  Van  de  patiënten  die  eerder  geen  depressieve 
symptomen  hadden,  ontwikkelde  één  op  de  vijf  patiënten  het  opvolgende  jaar wel 
depressieve symptomen. Daarvan liepen patiënten met een ernstig ziektebeeld extra 





Depressie  instrumenten kunnen de  clinicus helpen om depressieve  symptomen  te 
herkennen. Deze instrumenten kunnen zowel interviews betreffen, als vragenlijsten 
die  de  patiënt  zelf  in  kan  vullen.  Om  de  clinicus  te  helpen  bij  het  kiezen  van  een 
geschikt meetinstrument, geeft Hoofdstuk 3 een overzicht van depressie instrumenten 
die  toepasbaar  zijn  bij  patiënten  met  schizofrenie.  Op  basis  van  systematisch 
literatuuronderzoek  hebben  we  alleen  díe  depressie  instrumenten  geselecteerd 
voor  evaluatie,  waarvan  een  breed  scala  aan  gegevens  over  de  betrouwbaarheid 






die  de  ernst  van  de  psychotische  symptomen meten.  Het  CDSS  interview maakte 
het best onderscheid  tussen depressieve symptomen en negatieve symptomen van 
schizofrenie  (divergente  validiteit)  en  voorspelde  een  diagnose  van  depressie  het 
best  ten opzichte  van andere depressie  instrumenten bij mensen met  schizofrenie 
(voorspellende validiteit). Op basis van deze resultaten zouden wij willen aanbevelen 


























bijwerkingen  van  antipsychotica.  Op  basis  van  bovengenoemde  resultaten  zouden 
we zelf-rapportage van depressieve symptomen met de QIDS-SR16 vragenlijst willen 
afraden bij mensen met schizofrenie. 






met  behulp  van  de  CES-D  van  depressieve  symptomen  een  geschikte manier  kan 
zijn om depressieve symptomen te meten bij patiënten met schizofrenie. Bovendien 
lijken  de  depressieve  symptomen  die  worden  gemeten  met  de  CES-D  minimaal 








van dit  onderzoek was het  inkorten  van een  lange  vragenlijst  over ervaringen met 
antipsychotica.  Een  groep  van  1478  patiënten  met  schizofrenie  werd  gevraagd  de 
74 vragen van de Subjects’ Reactie op Antipsychoticagebruik (SRA-74) vragenlijst in 
te  vullen, om  te onderzoeken welke ervaringen ze  toeschreven aan antipsychotica. 
Met  behulp  van  factor  analyse  werd  de  samenhang  tussen  de  ervaringen  met 




waaronder  één  specifiek  over  depressieve  symptomen. Het  bestaan  van  de  aparte 
‘factor’ over depressieve symptomen (i.e. de vragen ‘door antipsychotica voel ik me 
depressiever  / meer down’),  impliceerde dat  deze  twee SRA-vragen  valide kunnen 
worden  ingezet  om depressieve  symptomen  in  reactie  op  antipsychoticagebruik  te 
onderzoeken. Daarnaast bleek dat een deel van vragen niet kon worden gegroepeerd 
onder één van de 14 onderwerpen. Deze vragen waren blijkbaar te weinig specifiek 
en  indien  ook  niet  klinisch  relevant  geacht  volgens  het  expert  panel was  besloten 
om deze vragen weg te laten in de verkorte versie. Dit resulteerde in een vragenlijst 
van  34  vragen,  waarmee  de  balans  tussen  gewenste  en  ongewenste  effecten  van 
antipsychotica met de patiënt kan worden geëvalueerd. 
Depressieve symptomen kunnen gerelateerd zijn aan de mate waarin antipsychotica 









per  antipsychoticum  was:  haloperidol  (91.9%),  risperidone  (92.4%),  olanzapine 




mogelijk  speelden  andere  methodologische  aspecten  hier  een  rol  in.  Leeftijd 
noch  geslacht  leken  de  verschillen  tussen  patiënten  te  verklaren;  misschien  dat 
individuele  verschillen  in metabolisme  hieraan  ten  grondslag  liggen. Hierdoor  zijn 
de curves niet geschikt om de D2  receptorbezetting  voor een  individuele patiënt  te 
schatten.  Desondanks  gaven  de  betrouwbaarheidsintervallen  van  de  curves  aan 











D2  receptorbezetting  in  de  hersenen.  Met  behulp  van  de  SRA  vragenlijst  werden 
patiënten gevraagd of zij depressieve symptomen toeschreven aan hun antipsychotica 
gebruik.  Van  de  1298  patiënten  die  onderzocht  werden,  schreef  16%  depressieve 
symptomen  toe  aan  antipsychotica  gebruik.  Analyse  met  logistische  regressie 
analyse kon echter geen verband tussen depressie symptomen en een bepaald type 
antipsychotica,  of mate  van D2  receptorbezetting  aantonen. Opvallend was wel  dat 






de  clinicus  wel  willen  adviseren  om  voorzichtig  te  zijn  met  het  voorschrijven  van 
een  combinatie  van  antipsychotica,  ter  voorkoming  van  bijkomstige  depressieve 
symptomen. 
slotwoord    Jaarlijkse  screening  wees  uit  dat  depressieve  symptomen  vaak 
voorkomen en persisteren bij mensen met schizofrenie, ondanks dat antidepressiva 




In  praktijk  kan  het  voor  de  psychiater moeilijk  zijn  om  depressieve  symptomen  te 
onderscheiden  van  andere  psychotische  symptomen,  zoals  negatieve  symptomen. 
Het  gebruik  van  gevalideerde  instrumenten  zoals  de Calgary Depression Scale  for 
Schizophrenia  (CDSS)  kan  de  psychiater  helpen  om depressieve  symptomen  beter 
te  herkennen.  Hiermee  kan  mogelijk  overdiagnostiek  en  overbehandeling  met 
antidepressiva worden voorkomen. De Center of Epidemiologic Studies-Depression 





Patiënten  schreven  depressieve  symptomen  vaak  toe  aan  het  gebruik  van 
antipsychotica.  Deze  depressieve  symptomen  leken  onafhankelijk  van  andere 
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Subsequently, she started her career  in clinical  research at  the University Medical 
Center  in  Groningen.  She  facilitated  the  implementation  of  the  PHArmacotherapy 
Monitoring and OUtcome Study (PHAMOUS) in the North of the Netherlands, where 





aspects  of  biomedical  statistics  and  psychiatric  epidemiology.  She  is  currently 





























































































antipsychotic medication, then the answer is: ‘yes, to a high degree’.
If, during the past week, you have had the idea that to a certain degree you think 
more clearly due to















1 My emotions are dull O O O EF
2 I feel happier O O O RA
3 My weight has increased O O O WA
4 I have less energy for socializing O O O SW
5 I can’t remember well O O O SD
Due to the antipsychotic medication:
6 I react more slowly O O O SD
7 I am less anxious O O O RP
8 I feel more depressed O O O DS
9 I am constipated more often O O O OU
10 I can concentrate better O O O RA
Due to the antipsychotic medication:
11 I leak urine more often O O O OU
12 My vision is more blurred O O O OU
13 I have more trouble sitting still O O O OU
14 I hear fewer voices O O O RP
15 It is more difficult for me to have an orgasm O O O SP
Due to the antipsychotic medication:
16 I have a dry mouth more often O O O OU
17 My memory has improved O O O RA
18 I have more tremors O O O EP
19 I have more interest in my surroundings O O O RS
20 I am nauseous more often O O O OU
Due to the antipsychotic medication:
21 My sex drive has decreased O O O SP
22 I am dizzy more often O O O OU
23 Dealing with others is easier O O O RS
24 I can think more clearly O O O RC









26 I have more difficulty waking up O O O IS
27 I am less creative O O O OU
28 My muscles are more stiff O O O EP
29 I have more control over my thoughts O O O RC
30 I have increased salivation O O O OU
Due to the antipsychotic medication:
31 I have more trouble concentrating O O O SD
32 I have an increased appetite O O O WA
33 I can sleep better O O O RIS
For females only:
34 I menstruate less often O O O OU
Concluding questions:
C1 I am satisfied with the antipsychotic medication O O O C
C2 I feel dependent on antipsychotic medication in order to function O O O C








































































































antipsychotische medicijnen dan is het antwoord: ‘ja, in sterke mate’.
Als u de afgelopen week het idee heeft dat u in enige mate helderder denkt door de 














1 Zijn mijn emoties afgevlakt O O O EF
2 Voel ik mij opgewekter O O O RA
3 Is mijn gewicht toegenomen O O O WA
4 Heb ik minder energie voor sociale contacten O O O SW
5 Kan ik minder goed onthouden O O O SD
Door de antipsychotische medicijnen:
6 Reageer ik trager O O O SD
7 Ben ik minder angstig O O O RP
8 Voel ik me depressiever O O O DS
9 Zijn mijn darmen vaker verstopt O O O OU
10 Kan ik mij beter concentreren O O O RA
Door de antipsychotische medicijnen:
11 Verlies ik vaker urine O O O OU
12 Zie ik waziger O O O OU
13 Kan ik moeilijker stil zitten O O O OU
14 Heb ik minder stemmen O O O RP
15 Heb ik meer moeite om een orgasme te krijgen O O O SP
Door de antipsychotische medicijnen:
16 Heb ik vaker een droge mond O O O OU
17 Is mijn geheugen beter O O O RA
18 Tril ik meer O O O EP
19 Heb ik meer belangstelling voor mijn omgeving O O O RS
20 Ben ik vaker misselijk O O O OU
Door de antipsychotische medicijnen:
21 Heb ik minder behoefte aan seks O O O SP
22 Voel ik me vaker duizelig O O O OU
23 Is het omgaan met anderen makkelijker O O O RS
24 Kan ik helderder denken O O O RC









26 Heb ik meer moeite met wakker worden O O O IS
27 Is mijn creativiteit verminderd O O O OU
28 Heb ik stijvere spieren O O O EP
29 Heb ik meer controle over mijn gedachten O O O RC
30 Heb ik meer speeksel in mijn mond O O O OU
Door de antipsychotische medicijnen:
31 Kan ik mij minder goed concentreren O O O SD
32 Heb ik meer eetlust O O O WA
33 Kan ik beter slapen O O O RIS
Alleen voor vrouwen:
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state-of-the-art analyses for hepatitis and rotavirus in Vietnam 
(prof MJ Postma, prof HJ Woerdenbag)
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